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INTRODUCTION 
 
 Wound infection is the foremost root cause of health care associated 
infection.Globally the morbidity and mortality caused by it rated to be 70-80% 
1
. Wound infection is defined as the invasion of organisms through tissues 
following a breakdown of local and systemic host defences, leading to 
cellulitis, lymphangitis, abscess and bacteraemia 
2 
 
 Wound is a kind of physical stress which are consequences of chemical 
or biological injury, with subsequent loss in the normal integrity of the skin or 
underlying tissue. In open wound it is seen as a cut or penetrating injury and in 
case of closed wound it occur as a blunt injury. 
3 
 
 Our body naturally tries to maintain the originality of the skin anatomy 
after an injury by the process of wound healing. Wound healing in turn is 
influenced by the level of contamination. Clean wounds usually heals without 
any barrier as they are free of microorganism. Contaminated wounds may 
contain the invading pathogenic microorganism or any foreign substance in it. 
These Pathogenic bacteria derives its nutrition from the uncovered 
subcutaneous tissue in wound and starts multiplying in it. When Infection sets 
in a wound, it is evident by the clinical signs of inflammation. while the 
severity of infection depends on the contamination level, immune status of the 
person, wound perfusion rate, its size, depth of invasion, microbiological load 
and its virulence factor. Aerobic and anaerobic bacteria, both can invade a 
wound
(4 , 3, 2) 
 2 
 
 
Previously to the discovery of antibiotics the root cause of wound 
infection was by group A beta hemolytic Streptococci. Since 1950 after the 
discovery of penicillin G, Staphylococcus aureus overruled the wound 
infection. But Pseudomonas aeruginosa from patients endogenous flora and as 
well as from the environment around us became the frequent sources of burns 
wound infection. At the same time growing population of new antibiotics 
resulted in evolution of more number of virulence factor in Gram negative 
bacterial like Escherichia coli, Klebsiella species, Proteus species and 
Acinetobacter. These factors multiplied the drug resistance in the bacteria and 
subsequently this made the infection to persist, thereby prolonging the process 
of wound healing.  
 
 Recent years shows sudden spurt in drug resistant in Klebsiella species. 
This has not only culminated in dreadful pneumonia but twisted the infection 
profile of Klebsiella species which includes a wide range of wound infection 
such as infection at surgical site, chronic ulcers (eg. Diabetic), burns wound 
infection, skin and soft tissue infection making it to be an important 
opportunistic organism that grounds for health –care related infection globally. 
The resistance apparatus in Klebsiella species are plasmid made which shapes 
several genes involved in several types of beta-lactamases resistance such as 
Extended spectrum beta Lactamases, carbapenemase and Amp c lactamases.
(5,6)
  
 
 Extended spectrum beta Lactamase was first recognized in Klebsiella 
species in the year 1983.Persistence of ESBL enzymes world wide were due to 
 3 
 
the transformation in TEM-1 and TEM-2 and SHV-I gene which causes 
hydrolyzation and inactivation of various types of beta lactam antibiotics.In 
Klebsiella species plasmid Ampc enzyme makes antibiotics like cephalosporin 
containing 7 methoxy and oxyimino groups and monobactams susceptible to 
it resulting in emergence of multi drug resistance strain. The preferred choice 
for treating these multiple drug resistant Klebsiella species were carbapenem 
group of drugs. But information from CDC in 2007 surprised that 8% of 
Klebsiella species were notorious for carbapenem resistant. First source of 
KPC was identified in 1996. While New Delhi Metallo-β-lactamase- rooted in 
klebsiella pneumonia was first seen in a patient from Sweden of Indian origin. 
Ultimately Klebsiella species landed up as pan drug resistant strain (PDR) 
featuring multiple treatment failures and thereby  increasing the death rate 
(CDC, 2009). 
7  
 
 In developing countries drug resistant among bacteria is not only 
complicated by injudicious use of antimicrobials, but also by poor infection 
control practice and overcrowding of patients in hospitals. Globally challenging 
to treat this resistant pathogens with antibiotics of higher level is not only too 
expensive but hospitalization of the patient is also prolonged. This has added to 
the growth of multiple drug resistanc gene in bacteria which ultimately 
increased the morbidity and mortality rate worldwide. 
 
 This study was undertaken to determine the prevalence of Klebsiella 
species in wound infection and also to study the importance of drug resistance 
shown by them. 
 4 
 
AIMS & OBJECTIVES 
 
AIM: To find the prevalence of Klebsiella species from wound infection and to 
find its molecular characterisation with special reference to carbapenem 
resistance. 
 
OBJECTIVE  
 To isolate, Klebsiella species from wound infection. 
 To characterize and speciate Klebsiella from wound infection. 
 To identify the antibiotic sensitivity pattern of the Klebsiella species 
isolated. 
 To detect the Exetended spectrum beta lactamase (ESBL) producing 
Klebsiella species by phenotypic method 
 To detect AMPC producing Klebsiella species by phenotypic method 
 To detect carbapenemase producing Klebsiella species by phenotypic 
method. 
 To do molecular characterization of the isolated carpbapenemase 
resistant Klebsiella species 
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REVIEW OF LITERATURE 
 
 Wound infection is one of the essential cause of health care related 
problem because the resulting wound is being colonised by pathogenic 
microorganism. Infection take place when the virulent factor of the 
microorganisms overrules the natural immunity of the host system. As 
microorganism invades the living tissue it easily get carried to different site, 
initiating several local and systemic inflammatory response.  
 
 History of wound care spans from prehistory to modern medicines. 
Untill the middle of 19th century, post operative patients started developing 
fever and purulent inflammation at their incisional site, ending up in sepsis and 
at times lead to death. As a result surgical site infection became very severe, till 
1860 surgeons failed to attempt on surgeries, which indicated that wound care 
was more essential.  
 
 In 2200BC people thought that wound healing occurs by proper-hand 
washing, bandaging and applying plasters. The Egyptians applied bandages and 
plaster to the wounds and made use of honey and greases for prevention of 
infection. Greeks by cleaning wound with vinegar and wine, emphasized on 
cleanliness of wound. Hippocrates the father of medicine dressed wound with 
sweet wine. The Austrian obstetrician Ignac Semmelweis brought down 
puerperal sepsis from 10 percent to 2 percent by encouraging hand washing.  
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 Greek classified wound as acute and chronic wounds. While the signs of 
inflammation like rubor, tumor calor et dolor were described by Romans. In 
1877 Koch, identified bacteria in wounds under the microscope. Louis Pasteur 
in his germ theory proved that infection in human being are due to 
microorganism. But the field of surgery was revolutionized by the antiseptic 
technique introduced by Louis pausteur.  
 
 Discovery of Penicillin, payed way for a new era in wound infections 
management. In mid-20ies „magic bullet‟ (Zauberkugel) concept insisted to kill 
microbes but not their host. This lead to the invention of sulphonamide 
chemotherapy.
2
  
 
PATHOPHYSIOLOGY OF WOUND 
 Skin acting as the natural barrier, is the largest organ in our body both in 
terms of surface area extension and weight. It naturally senses any difference in 
body temperature, and defenses against the invasion by micro-organisms. It 
protects from radiation effect and from chemical hazards. It maintains normal 
temperature and fluid balance in our body through the effect of sweat glands 
and follicles present in the hair. It is one of the most sensitive organ being 
highly supplied with network of nerve cells which quickly senses any variation 
in the environment covering us. 
 
 Wound occurs when skin losses its defensive mechanism.It results from 
all kind of surgical injury, burns injury, different types of bites, or from any 
type of diseases which compromises the integrity of skin. Injury provides, good 
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nutrition to the microorganism which multiplies in a suitable environment like 
ischemia and hypoxia causing damage to tissue which release the toxin causing 
wound infection. While the level of tissue perfusion, the wound type, its 
location, depth of invasion, and the quantity of antimicrobial load influences 
wound healing process. 
3 
 
wound healing: 
 Repairing of wound is known as wound healing 
The phases of wound healing are 
 The inflammatory phase 
 The proliferative phase 
 The Remodeling phase (maturing phase). 
 
 Inflammatory phase begins by activating the clotting system making the 
platelets to aggregate with formation of fibrin clot thereby stoping the bleeding 
(haemostasis).While the released thromboxane and prostaglandin results in 
constriction and dilatation ot the vascular system. On reaching the injured site 
the Neutrophils, Macrophages and Monocytes phagocyte the bacteria and 
release proteases that removes the damaged tissues. In. Proliferative phase new 
blood vessel are formed resulting in angiogenesis. Fibroblast and collagen get 
deposited and granulation tissue are formed. Epithelial cells by bridging across 
granulation tissue makes the wound to contract. when synthesis and destruction 
of collagen equalize, Maturation and Remodeling sets in and is influenced by 
wound size. 
 8 
 
 Wound healing is compiled by both acute inflammation and chronic 
inflammation. Acute inflammation are results of dilation of arterioles and 
capillaries which rushes the blood flow to the injured part sensed by signs of 
inflammation which are caused by the toxic metabolite released by 
inflammatory mediator. They are red (rubor), heat (calor), and swelling (tumor) 
and painful (dolor). When the inciting agents are not cleared, it leads to 
Chronic inflammation and characterized by odour, gapping of the wound, 
increased wound size, bleeding, discoloration of the tissue, erythema, increase 
in pain, friability of tissues, wound pocketing, and pus formation. 
 
 Scar occurs when inflammatory phase is prolonged and accumulation of 
excessive disorganized granulation tissue 
(8,5,2)
. 
 
Pathogenesis of wound infection 
 Phagocytosis take place when it overcomes the microorganism. It 
releases cytokines, lipid messenger and inflammatory mediators which 
activates the leucocytes and clears the infectious agent  
 
 Active immune system suppress the inflammation and initiate wound 
healing process. Breakthrough in immune system results in suppurative or 
purulent inflammation caused by pyogenic bacteria, leading to purulent exudate 
formation, comprising interstial fluid, liquefactive necrosis, and degenerated 
neutrophil cells. Abscesses are localization of purulent inflammatory cells 
within a tissue, or in to an organ, or to a spaces which is confined. Improper 
assimilation of granulation tissue makes the wound to be delicate and ulcerate. 
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 These wounds are notorious for rupturing most frequently seen in case 
of abdominal surgery. Non healing ulcer are consequences of chronic 
inflammation mostly resulting in sensational loss, most commonly encountered 
in peripheral neuropathy as a complication of diabetes.  
 
 Acute wounds are normally inhabited by monomicrobial bacteria mostly 
occupied by gram positive bacteria. But chronic wounds are loaded with poly 
microbial organism and ascended by aerobic gram negative pathogen, 
anaerobes and aerobic gram positive organism 
(8,2) 
 
RISK FACTORS OF WOUND INFECTION. 
 Age (e.g. children an older patients),  
 Chronic illness (e.g.diabetes mellitus, chronic pulmonary disease, 
vascular disease), Medications (e.g. Anticancer drugs, anti- coagulant and 
steroids) and lifestyle factors (e.g. smoking and alcohol)  
 
CLASSIFICATION OF WOUND 
1.Based on the duration of wound 
 Wounds are classified into Acute wounds and chronic wounds. Damage 
to the skin by an external sources are Acute wounds and these wounds heal 
spontaneously and quickly.  
 
 Chronic wounds are endogenous in nature and takes more time in 
wound healing process. Eg. Foot and pressure ulcer resulting from inadequacy 
of blood supply and when venous drainage is not proper., is usually seen in 
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diabetes mellitus, chronic smokers, elderly patient, obesity, malnutrition, and 
immunocompermissed. 
8 
 
2.According to rank wakefield classification 
Tidy wounds - Caused by sharp objects. Healing is by primary intention as they 
have no devitalized tissues 
Untidy wounds - results of crushed injury, avulsion of tissue, vascular and 
burns injury. Healing is by secondary intention as it has devitalized tissues in 
it.
2 
 
3. Endogenous wound are caused by commensals bacteria is otherwise known 
as autoinfection and Exogenous wound infection are from environmental 
sources or otherwise called as cross infection
9.
  
 
Depending on their etiology 
BURNS WOUND 
 Burn is defined as an injury to the skin or other organic tissue primarily 
caused by heat or electricity, radiation and by chemicals 
 
 In thermal injury, burns surfaces are usually sterile initially but later on 
they are invaded by microorganisms 
( 10,11)
Initially up to 48 hours, colonization 
of wound is done by Gram-positive cocci like Staphylococcus aureus as they 
are situated within depth of the sweat glands of the skin and hairfollicles
(10,12,13)
 
and after a time interval of 56 to 7 days later they are invaded by both gram-
positive and negative bacteria, and as well as by yeasts cells.The source of 
infection is from patient‟s own normal flora and can also be derived from the 
 11 
 
hospital environment and these organism are also present in the hands of the 
health care persons
(10,12,14,15,16,17,18) 
 
 
When burns wound occupies larger surface area it compromises the 
blood supply to the tissues producing necrosis. This leads to eschar formation. 
This causes bacteria to multiply.
11, 18, 19,.
The resulting escar releases toxin which 
limits the passage of systemic antibiotics to the involved area making the 
infection to persist. (Immunological Response to Burn Injury
 
)
20 
 
 Resulting inflammation moves the fluids, electrolytes and proteins to 
extravascular space from the intracellular space causing loss of fluid which is 
in direct proportion to the burnt surface area. When the Total burnt surface area 
is more than 15 per cent of surface area, ensuing fluid loss precipitate shock 
and such patients usually have central monitoring lines and catheters, making 
the condition more complicated as these devices serves as source of infection.
2 
 
EPIDEMOLOGY 
 Burns being growing health problem globally accounts for 180,000 
death yearly. According to World health organization 300,000 people die of 
burns yearly and approximately 95% of it is from the developing countries. In 
S.E.Asia more than 57% of burns death is noted. In India, the second common 
cause of all injuries is due to burns and accounts for seven million cases yearly. 
When the TBSA is< 40%, the rate of survival is 50% and 100000 death and 
200000 disabilities. (Practical hand book on burns management & national 
health portal 
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 According to National burns repository report from 2008-2017, death 
rate is > 67% when the body surface area and age is more. When the burnt size 
n< 10% TBSA, 0.6% is the mortality rate. 55% of burns injury is seen within 
age group of 20 to 59 and when the age is 60 and above the estimated mortality 
rate was 15%. The survival rate was higher who had greater than one day stay 
per % TBSA. Mortality was higher who stayed for 2-3 weeks with %TBSA < 
80%.
1 
 
ETIOLOGY OF BURNS: 
 Thermal injury include flames and hot surface of any items or hot 
liquids that causes (scald), source of heatis in the form of conduction, 
Convection, radiation injury 
 
 Chemical injury, injury from an oxidizable or reducing agents and 
corrosive substances. 
 
CLASSIFICATION OF BURNS 
First-degree burn: Involves the epidermis with erythema formation. No blister 
is formed 
 
Second-degree burn  
 Superficial burns involves both epidermis and papillary dermis and deep 
or partial thickness burns involves the reticular dermis. 
  
Third-degree burn or full-thickness burns.: along with epidermis and dermis, 
subcutaneous tissue are also involved.  
 13 
 
Fourth-degree burn : Invades deeper subcutaneous tissue along with muscle, 
fascia, or bone 
 
 TBSA is calculated from The rule of nine. Involvement of upper limb is 
9 per cent TBSA and lower limb is18 per cent. The torso accounts for18 
percent on each side and head and neck accounts for 9 % each
2.
  
 
 SURGICAL SITE INFECTION 
  Surgical site infections, the chief cause of healthcare-associated 
infection
1
 lines 3 rd in origin of nosocomial infection. Hospital-acquired 
surgical-site infection previously known as “Hospitalism was named by Sir 
James Simpson 
21 
 
 It is also described as “The Silent Killer of nosocomial Infections” 
because it resulted in minor illness to severe dangerously ill infection and 
resulted in utilization of all modern medicinal resources
22
. 
 
 Centers for Disease Control and Prevention (CDC) defined surgical site 
infection as infection related to an operative procedure that occurs at or near 
the surgical incision within 30 days of the procedure or within 90 days if 
prosthetic material is implanted at surgery
(23,2)
 and for surveillance purposes it 
categorized the SSI into 
category 1- purulent drainage is present. 
category 2- aseptically collected specimen are culture positive 
category 3- Culture is not negative and showing any one sign of inflammation 
category 4- physician diagnosis
(23)
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Classification depends on depth of incision: 
 Incision involving skin and subcutaneous layer causes superficial 
infection. Incision involving deeper tissues or Organ/space causes deeper 
infection as defined by CDC
23,4 
 
SSI as defined by WHO clinically: “a purulent discharge surrounding the 
wound or the insertion site of the drain, or spreading in cellulitis around the 
wound” 
 Globally, it is reported to ascend from 2.5 to 41.9 per cent. A recent 
surveillance by INICC in India, it is2 to 21%.
24 
 
The classification of operative wounds based on the degree of microbial 
contamination are as follows  
Clean: Elective surgery and not-traumatic. Closes by primary intention, and 
without acute inflammation. Does not enter into any system othe body. 
 
Clean contaminated: Emergency but it is clean; clean opening of all the system 
with minimum spillage (eg:appendicectomy). Bile and urine are not infected 
here. 
 
Contaminated:Inflammation is not purulent.There is gross spillage from 
gastrointestinal tract; entering into the biliary/ genitourinary system even when 
the bile/urine is infected.  
 
Dirty: Inflammation is purulent (abscess); perforation of the organ system. And 
includes penetrating trauma >4 hrs old.) 
23,2 
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Sources of surgical wound infections includes patients normal flora or 
organisms from surrounding environment. The type of wound infection 
depends on whether the surgery is elective or emergency, pre antibiotic 
prophylaxis taken, placement of drainage tube and associated comorbid 
condition like anemia, diabetes mellitus, chronic smoking and chronic diseases.  
 
DIABETIC FOOT ULCERS  
 Diabetic foot can be defined as any foot pathology that results directly 
from diabetes mellitus or its prolonged complication. The principle 
complication of chronic diabetes is diabetic foot ulcers 
 
 IWDGDF estimates DFU to be 8.4%6.3%-R16 while the prevalence of 
foot ulcer in diabetic patient is from 12%to 25% -R28. In India diabetic foot 
ulcers ranges from (7.3% - 24%). 8,9
25 
and in South India it is reported to be 
11%.
26
  
 
 Guidelines from The British Association of Dermatologists, The 
Consensus Development Conference on Diabetic Foot Wound Care andthe 
Royal College of Physicians denotes that wound is said to be infected when 
fever along with, increasing in size of ulcer is associated with intolerable pain, 
increasing erythema surrounding the skin and lymphangitis
26
. Chronicity is due 
to impaired wound healing resulting in defective granulation tissue formation
8
. 
Infection in a diabetic wound are sually polymicrobial in nature and mostly 
invaded by gram positive and, gram negative bacteria, anaerobes, and also 
invaded by Fungus like Candida species and Tinea.,  
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Wagner grading system is used for Diabetic foot ulcer classification. 
MODIFIED WAGNER’s CLASSIFICATION SYSTEM 27 
GRADE LESION 
O - No open lesion may have deformity or cellulites 
1 - superficial ulcer, 2 - deep ulcers to tendon or joint capsule, 3 -Deep ulcers 
with abscess and osteomyelitis, 4 -Localized gangrene- forefoot or heel and  5 - 
Gangrene or entire foot.Each grade is further divided into A & B. A 
representing ischemia and B infected.  
 
BITE WOUNDS 
 Bite wounds are caused by domesticanimals, wild animals, and humans. 
Prevalence of bites seen in 4.7 million Americans yearly and with severity of 
infection 1%. Infections results from patients own skin and oral flora and also 
from the environment,
1 
 
ABSCESS 
 An abscess is localized collection of pus caused by Pyogenic organism. 
Pus are collection of degenerated white blood cells which causes acute 
inflammation by generating free radicals and cytokines. Chronic abscess results 
when acute abscess are not drained incompletely and also sinus or fistula 
formation take place. chronic abscess are mostly caused by Mycobacterium 
species and Actinomycetse. Inadequately treating with antibiotics results in 
antibioma. Abdominal abscess are due to anastomotic leakage. Deep seated 
abscess take place in pleura and pericardium
1, 2 
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PRESSURE ULCERS 
 It is defined as tissue necrosis resulting in ulceration due to prolonged 
pressure. It includes bed sores, decubitus ulcers and pressure ulcers. 5 per cent 
of hospitalized Patients suffer from pressure ulcer.  
 
According to American National Pressure Ulcer Advisory Panel, the stages of 
pressure ulcer are 
stage1 - Non-blanching erythema with intact epidermis 
stage 2- involvement of epidermis and dermis with Partial-thickness loss 
stage 3- involvement of subcutaneous tissue without underlying fascia results 
in Full-thickness loss 
stage 4- Fascia, tissue, underlying muscle, bone, tendon or joint involvement 
causes Full-thickness loss
2 
 
NECROTISING SOFT-TISSUE INFECTION 
 They produce devasting tissue infection and are polymicrobial in nature. 
Mostly it is invaded by Gram-positive cocci like Staphylococcus aureus, β 
haemolytic Streptococcus and Streptococcus pyogens. On the other hand gram-
negative aerobes like E.coli and Pseudomonas, and anaerobes like Clostridium 
and Bacteroides causes infection.It is results of microorganism immediately 
colonizing the wound after a trauma or surgery and shows a rapid progression. 
This includes gas gangrene caused by clostridium bacteria and necrotizing 
fasciitis are caused by streptococcal organism also known as flesh eating 
bacteria.
1,2
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Microorganisms causing invasive wound infection 
Bacteria: Gram positive bacteria: Staphylococcus aureus, Coagulase-negative 
staphylococci and Enterococcus spp. 
 
Gram- negative organisms: Pseudomonas aeruginosa, Escherichia coli, 
Klebsiellapneumoniae, Serratia marcescens, Enterobacter spp, Proteus spp, 
Acinetobacter spp and bacteriods 
 
Fungus: Candida spp, Aspergillusspp, Fusarium spp, Alternaria spp, Rhizopus 
spp and Mucor spp. 
 
Virus: Herpes simplexvirus, Cytomegalovirus and Varicella-zoster 
 
 Recent data shows community- and hospital-acquired infection showing 
an increasing trend in the rate of infection caused by Klebsiella 
species.injudicious use of broad-spectrum antibiotics lead to the development 
of multidrug-resistant strains with increasing carriage of klebsiella species in 
hospitalized patient, since it carries genetic material that can be easily 
transferred horizontally by the transposons and plasmids 
7,5,6 
 
Klebsiella pneumoniae 
 Klebsiella or Friedlander‟s bacillus is named after Edwin Kleb. 
Klebsiella species are found to ubiquitous in nature as they inhabit ate soil and 
water. In humans being, they commensal the gastrointestinal tract.  
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Morphology of klebsiella species. 
 Klebsiellae species belongs to the family of Enterobactericeae. They are, 
gram-negative short, straight rods of 1-2μm long and breadth o.5 -0.8 μm with 
parallel sides and rounded edges. They occur either singly or scattered in pairs 
and have a prominent mucopolysaccharide capsule , producing thick mucoid 
colonies
28,29
 
 
Antigenic structure of klebsiella 
Klebsiella species on their cell surface bears two type of antigenic structure. 
The lipopolysaccharide O antigena nd polysaccharide capsular K antigen. 
There are about 77 K antigens and 9 O antigens 
28
. 
 
CLASSIFICATION OF KLEBSIELLA SPECIES
28,7,9 
 Depending on 16Sr RNA sequences and rbogene it is grouped as 
clusters. Cluster I is formed by klebsiella pneumoniae subspecies pneumoniae, 
klebsiella pneumoniae subspeciesrhinoscleromatous, klebsiella pneumoniae 
subspeciesozaenae and klebsiella granulomatis. Cluster II contains klebsiella 
ornithinolytica, klebsiella terrigena and klebsiella planticola and while cluster 
III is framed by klebsiella oxytoca and Klebsiella treisani  
 
VIRULENCE FACTOR OF KLEBSIELLA
31
 
 The four important virulent factor of Klebsiella pneumoniae are capsule, 
fimbrae type (1&3), lipopolysaccaride(LPS) and Siderophores. 
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Capsule 
 It forms the outer envelope and made up of extra poly saccharide matrix. 
It contains 77 serotype of capsular antigen (k77) of which k1 & k2 are potent 
antigen causing serious infection. Hyperviscous capsule produces hypervirulent 
strain. (topley & mandel). It protects the organism from phagocytosis, 
bactericidal effect of antibioticss, from opsonisation effect, complement lysis 
and protects bacteria from injury caused by free radical, interlukin 8 and TNFᾳ  
The capsular production gene is found on chromosome operon cps. 
 
 The cps cluster gene, the plasmid regulatory gene (rmpA & rmpa2) and 
the capsule regulatory gene (rcsA and rcsB) help in capsule formation 
 
LIPOPOLYSACCARIDE 
 LPS is seen in the bacteria cell membrane which produce exotoxin. It 
contains lipidA, oligosaccharide and antigen O. Of 9 O antigen, O1 is the most 
potent antigen. They contain wb, waa, and lpx gene. Lipopolysaccharides 
(LPS) protects the bacteria from cell death by preventing the formation of 
membrane attack complex (C5b-C9 Smooth LPS resist complement lysis and 
rough LPS are destroyed by complement lysis 
 
FIMBRIAE TYPE 1 & 3 
Type 1- fimbriae are chaperone-usher family containing filamentous in nature 
and are membrane bound which contains fimA protein that bridges the fimG 
and fim H subunits. responsible for formation of biofilm and bladder mucosal 
invasion. 
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Type 3 fimbrae are helical in nature and membrane bound. They contain. MrkD 
and MrkA subunits. Important for forming biofilms on medical devices. 
 
SIDEROPORES 
 Iron binding protein sideropore is important virulent factor for causing 
infection. 
 
 Enterobactin, salmochelin, yersinibactin and aerobactin are important 
sideropores. Helps in colonising and bacterial dissemination. lutA, febA, IroN 
and ybtO helps in transportation of sideropores various sites. 
 
Infection caused by klebsiella species 
 Klebsiella pneumoniae the most important cause of Pneumonia. 
Diabetes mellitus, alcoholic and COPD are the predisposing factor. It can cause 
Respiratory tract infection, urinary tract infection, septicemia, pyogenic 
infection, meningitis and surgical site infection, wound infections, intravascular 
infection biliary tract infections, and peritonitis. In Asian countries liver 
abscess are most commonly caused by klebsiella species. And may also result 
in endophthalmitis 
 
 Klebsiella pneumoniae subspecies rhinoscleromatis causes 
rhinoscleroma a chronic granulamatous condition characterized by foul 
smelling nasal discharge affectig American, African and Asian population. 
 
 K. pneumoniae subspecies ozaenae colonizer of nasopharynx produces 
chronic atrophic rhinitis (ozena) in patients with otitis media and mastoiditis 
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infection. It can also cause pyelonephritis, soft tissue infection and bacteremia 
and differs from, K. pneumoniae by being indole positive. It is responsible for 
haemmorhagic colitis and broad range of nosocomial Infections.
28,9,7,6,5,1
  
 
Identification of klebsiella species
32,28,9,7
 
 They are Gram negative bacilli, non motile, oxidase negative and 
catalase positive. They ferment most of the sugars with production of acid and 
abundant gas. Production of gas from starch is important diagnostic feature of 
klebsiella. Produce oxidative fermentation reaction, reduce nitrate to nitrite, 
hydrolse urea and utilysis citrate. They are positive for voges proswaker 
reaction and negative for methylred reaction. On nutrient agar  it produces grey 
white mucoid colonies, because 92% of capsule is made of water. On nutrient 
broth due to increased viscocity it gives a gelatin like appearance. But strictly 
speaking it does not liquefy gelatin (topple). On Macconkey agar they produce 
Lactose fermenting mucoid colonies. 
species indole vp citrate urease gas malonate lactose lysine kcn 
klebsiella pneumonia 
subspecies aerogenes 
- + + + ++ + + + + 
klebsiella pneumoniae 
subspecies pneumoniae 
- - + + + + + + + 
subspeciesrhinoscleromatous - - - - - + - - ± 
klebsiella pneumoniae 
subspeciesozaenae  
- - ± - ± - ± ± + 
klebsiella ornithinolytica + ± + + + + + + + 
klebsiella planticola ± + + + + + + + + 
Klebsiella terrigena - + + - - + + + + 
Klebsiella oxytoca + + + + + + + + + 
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 Treatment of klebsiella infection 
 klebsiella pneumoniae are susceptible to broad spectrum antibiotics like 
pencillins groups, cepalosporins groups, Trime thoprim – sulphonamides 
aminoglycosides drugs and florquinolones groups but shows intrinsic 
resistantance to ampicillin  
 ESBL resistant strains show resistant to.Fluoroquinolone, aminoglycosides etc 
 Empirical treatment for complicated health care–associated Klebsiella 
species infections are Amikacin or carbapenems. Resistance to these 
antibiotics are also noted. 
 These resistant strain are treated with Tigecycline, polymyxin B, and 
colistin 
5
 
 
SAMPLE COLLECTION 
 In wound infection good sampling technique is necessary, because 
wound surface has the chance of getting colonized with bacteria present in the 
environment around us.Microbiological investigation to be effective it needs a 
detail history about the wound and thorough inspection of the wound site, for 
its position (ie:superficial or deep), type of wound (Eg. Surgical site infection, 
traumatic ulcer or pressure ulcer), discharge type, odour and clinical signs of 
infection. 
 
 Specimen collected should be devoid of contamination from the 
surrounding wound structure and its secretion. Sampling should always be 
from deeper part of the wound and Preferred samples are tissues and aspirates 
rather than a swab 
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TYPES OF SPECIMEN
33,9,7,4
 
Wound fluid sampling :  
 Fine needle aspiration are recommended for collecting pus from an 
abscess site. Incision and drainage of an the abscess are  the other choices. 
Sometimes the abscess itself can rupture spontaneously. But however adequate 
quantity of the specimen is required for investigation.  
 
Wound tissue sampling :  
 The leading edge or base of the ulcer are the preferred site for biopsy. If 
it is a cellulites wound, inject normal saline into it and then aspirate. 
Dermabrasion are also one of the the recommended method for burns wound 
tissue sampling  
 
Wound swabbing:  
 Swabs are advised only when tissues and aspirates are inadequate. 
Swabs like Dacron or Rayon polyester are best.As flocked swabs yield good 
amount of specimen it can also be used. Two swabs specimen are required and 
should be always from the deeper part. Dry ulcers after moistening with normal 
saline or sterile broth, then swabs are taken from it. All samples should be 
transported immediately to the laboratory.  
 
ANAEROBIC CULTURE 
 For anaerobic culture the exudates should be free of bubbles. Samples in 
a syringe along with needles should be rejected. Tubes and vials having 5% 
co2, reazurin the indicater and substances containing reducing agent are 
encouraged for transportation. 
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TRANSPORT OF SPECIMEN 
 Amies or Staut‟s transport medium with or without added charcoal are 
the recommended medium for transportation. Tissue sample are kept on a 
sterile guaze by moistening with nonbacteriostatic saline and it is transported 
quickly in a leak-proof sterile container to the laboratory and inoculate it on a 
culture plates within 1 to 2 hours of receiving the sample. 
 
Anaerobic culture,  
 Prereduced (PRAS) or Amies transport medium are preferred. 
Anaerobic bacteria although being the most important cause of wound 
infection, it is a complicated process to culture and process it. So Anaerobic 
processing is not usually proceeded in routine microbiological investigation.  
 
Processing of Wound Specimens
9 ,7
 
 Wound samlple requires thorough naked eye examination for its colour, 
odour and quantity. Examination of gram stained film,. culturing on 
Macconkey agar, Nutrient agar and cooked meat broth., scrutinize the 
microbiological test and antimicrobial susceptibility test reports. 
 
Gross morphology 
 It emphasizes on adequacy and the consistency of sample. Regarding 
consistency Staphylococcus aureus produces creamy and thick pus and it is 
watery in case of Streptococcus. Presence of granules indicates fungal 
infection. Production of blue pigmentation is seen with Pseudomonas 
aureginosa. Based on odor production, proteus species produces fishy odour, 
Pseudomonas gives sweet musty odor while anaerobic organism are identified 
by its putrid smell 
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MICROSCOPIC EXAMINATION 
 Gram staining : Its a differential stain used for differentiating the bacteria, 
IT serve as a preliminary report for starting an empirical therapy by the 
physician in case of life threatening infection. But most wound being 
polymicrobial, it is predicted that poor correlation is always shown between 
Gram smear and its corresponding culture results. 
  The actively moving bacteria and fungus are appreciated in wet film smear. 
 Modified acid fast staining for chronic wounds, as it is  mostly caused by 
Mycobacteriums pecies and Nocardia species. 
 
Cul turing of wound sample.
5,7,3 
 Specimen received in the laboratory are streaked on Macconkey agar 
plate, Nutrient agar, blood agar plate for aerobic bacteria and for anaerobic 
bactreria inoculated on to a blood agar plate as it contains nitrogen/hydrogen 
plus 5% co2. Quantitative culture is a prolonged process and requires more 
time.since this procedure is more complex it is not recommended routinely. At 
the same time semiquantitative culture which is easier to do gives results 
similar to quantitative culture.  
 
BIOCHEMICAL TEST
34,28,9,7,3
 
CATALASE TEST 
 Catalase producing bacteria on addition of 3% hydrogen peroxide (3% 
H,0,) in presence of catalase enzyme gives nascent oxygen which is indicated 
by the prescence of brisk effervescence 
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OXIDASE TEST 
 It spots the existence of cytochrome oxidase enzyme with l% 
tetramethyl para-phenylenediamine dihydrochloride by generating deep purple 
colour within 10 seconds 
 
HUGH LEIFSON TEST 
 ByHugh and leifson test bacteria can be differentiated into fermentative 
or oxidative  
 
NITRATE TEST 
 Nitrate reductase enzyme reduces nitrate to nitrite present in the young 
culture of nitrate broth. 
   
INDOLE TEST 
 Tryptophanase enzyme breaksopen the the amino acid tryptophan to 
release indole. This change is noticed by formation of fuscia red colour on 
adding Kovacs reagent (para dimethyl amino benzoic acid) to overnight 
incubated peptone broth 
  
METHYL RED TEST  
 In glucose phosphate broth, bacteria ferments glucose to produce 
stronger acids (lactic, acetic or formic) that maintain the pH below 4.4, which 
turns methyl red indicacor from yellow colour to red color 
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VOGES- PROSKAUER  TEST 
 In glucose phosphate broth certai n bacteria produce acetoin (acetyl 
methyl carbinol) as chief end product of glucose fermentation. Acetoin is 
oxidized to diacetyl compound by 40% KOH and atmospheric oxygen, This 
reacts with a-naphthol to give red color  
 
CITRATE TEST 
 Carbon is produced from citrate and used as only source of energy. It is 
tested with simmon citrate medium.  
 
TRIPLE SUGAR IRON AGAR TEST 
 It indicates three properties like acid or alkaline production, with or 
without gas and hydrogen sulphide production. It contains Three sugars-
glucose, sucrose and lactose in the ratio of 1:10:10 parts. Indicator for acid 
production is phenol red. Ferric salt is an indicator to detect hydrogen sulfide 
(H2S) production.  
 
UREASE TEST 
 Urease enzyme hy drolyse urea into ammonia that makes the medium 
alkaline and turning it into pink colour 
 
MANNITOL MOTILITY TEST 
 It detects the both mannitol fermentative activity and motility of the 
organism 
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SUGAR FERMENTATION TEST 
  The ability of an organism to ferment a specific carbohydrate (sugar) 
indicated by production of acid detected by colour change, along with or 
without production. Glucose, lactose, sucrose maltose and mannit ol are widely 
used for sugar fermentation. 
 
LAO DECARBOXYLASE TEST 
 It detects the presence of substrate specific decarboxylase enzyme in the 
bacteria that break down amino acids, such as lysine, arginine and ornithine to 
produce alkaline byproducts which change the color of the indicator to purple. 
Cresol red and bromocresol purple are used as indicacors. 
 
ANTIBIOGRAM DISC DIFFUSION BY KIRBY-BAUER METHOD 
BACKGROUND 
9,7,3 
 The Kirby-Bauer test or the disk-diffusion method, is done on the 
Mueller-Hinton agar to test the antibiotic sensitivity and resistant pattern of an 
organism in order to treat an infection. The “zone of inhibition” exhibited by 
the organism is measured by a scale and compared with the criteria deliberated 
by the Clinical and Laboratory standard institute(CLSI). Then it is sort out into 
Susceptible (S)., Intermediate (I) or resistant bacteria. 
 
β- Lactam antibiotics 
 β- Lactam antibiotics include Penicillins groups, Cephalosporins groups, 
Monobactams drugs and Carbapenem groups 
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 β-lactam ring in β-lactam antibiotics posses 3 carbon atoms and single 
nitrogen atom. Difference in ring structure is characterize the antibiotic group.  
 
Mechanism of Action of β-lactam antibiotics:  
 β-lactam antibiotics interferes with the cell wall synthesis by targeting 
trans peptidases and by preventing the cross linkage of the peptidoglycan chain 
it causes osmotic instability leading to cell death of the bacteria  
 
Mechanism of resistance to β-lactam antibiotics:- 
 Resistance to beta-lactam antibiotics are by several mechanism. 
 Hydrolysisation of beta lactam ring by betalactamase.  
 Utilization of betalactam insensitive cell wall transpeptidases,  
 Efflux pumps present in Gram-negative cells pumps out the beta-lactam 
molecules  
 Beta lactamases located in periplasmic space of Gram-negative bacteria, 
puts a defensive mechanism against the antibiotics, thereby preventing it 
from reaching the target site. 
 Resistant gene either sits on on a chromosomes or plasmids which are 
easily transferrable. 
 
Classification of beta lactamases:-
36 
1. Oldest classification was by Richmond and Sykes framed by substrate 
profile and loci of the genes encoding the β-lactamases. 
2. Newer scheme includes molecular structure was framed by Ambler. 
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Bush 
Jacoby 
(2010) 
Bush 
Jacoby 
(1995) 
Ambler Antibiotic 
Substrate 
Inhibited by Representative 
Enzymes CA or 
TZB 
EDTA 
1 1 C Cephalosporins No No Amp C, ACT-1, 
CMY-2, FOX-1, 
MIR-1 
1e NI C Cephalosporins No No GC1, CMY-37 
2a 2a A Penicillins Yes No PC 1 
2b 2b A Penicillins and early 
cephalosporins 
Yes No TEM-1, TEM-2, 
SHV-1 
2be 2be A Extended spectrum 
cephalosporins, 
monobactams 
Yes No TEM-3,SHV-2, 
CTX-M, PER-1, 
VEB-1 
2br 2br A Penicillins No No  
2ber NI A Extended spectrum 
cephalosporins, 
monobactams 
No No TEM-50 
2c 2c A Carbenicillin Yes No  
2ce NI A Carbenicillin,Cefepime Yes No  
2d 2d D Cloxacillin Variable No OXA-01, OXA-10 
2de NI D Extended spectrum 
cephalosporins 
Variable No OXA-11, OXA-15 
2df NI D Carbapenems Variable No OXA-23, OXA-48 
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2e 2e A Extended spectrum 
cephalosporins 
Yes No Cep A 
2f 2f A Carbapenems Variable No KPC-2, SME-1. 
IMI-1 
3a 3 B(B1) Carbapenems No Yes IMP-1, VIM-1, 
CcrA, IND-1 
3b 3 B(B2) Carbapenems No Yes CphA, Sfh-1 
NI 4 Unknown     
 
Detection of β-lactamases9  
1. Acidometric method denotes any change in Ph 
2. Iodometric method: pencelloic acid on combining with starch reduces 
iodine to form blue colour 
3. Chromogenic cephalosporin method – denoted by change in colour. 
Hydrolysisation of β-lactam ring makes yellow Nitrocephin to change to red 
colour.
 
 
 β-lactamase inhibitors safe guards and protects the antibiotics from 
damage by combining with it either reversibily or irreversibily. Clavulante, 
sulbactum and tozabactum are the inhibitors which is usually found in 
combination.
 
 
Extended spectrum beta lactamase 
36,7,1
 
 ESBLs are collection of enzymes mostly seen in the family of 
Enterobacteriaceae About 300 different types of ESBLwere notified. These are 
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clustered into nine various groups depending up on the sequence in amino acid. 
The important once are temoneira (TEM) and sulfhydryl variable (SHV) and 
cefotaximase (CTX-M) type which is encountered inthe environmental species 
of Kluyvera capable of hydrolyzing both cefotaxime and cefriaxone. SHV-type 
ESBLs are most common type noted. In1983 in Germany, a kind of beta-
lactamase in Klebsiella ozaenae was identified to hydrolyze cefotaxime,. 
Which on sequencing proved to be SHV-2 lactamase which had serine in place 
of glycine at 238 position. Since then a SHV-2 lactamase became popular g 
lobally.  
 
TEMbeta-Lactamases 
 The TEM-designated asTemoneira or TEM was first seen in Escherichia 
coli from Athens. it is of two types the TEM-1 and TEM-2 and they were found 
to hydrolyzes ampicillin but were susceptible to extended-spectrum 
cephalosporins and were not inhibited by Clavulanic acid. 
 
 In 1987, CTX-1 isolated from Klebsiella actively hydrolysed cefotaxime 
and so they were coined as TEM-3. R20 It is due to extensive use of first 
generation cephalosporin has lead to selection pressure on third-generation 
leading to extensive resistant pattern. 
 
Inhibitor Resistant TEM β -Lactamases (IRT) : 
 In early 1990‟s B.Lactmases was found to be resistant to inhibitory 
action of clavulanic acid was notonly demonstrated in Escherichia coli but also 
in K.pneumoniae, K oxytoca, P.mirabilis, citrobater. freundii.–but fortunately 
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they weres sensitive to inhibitor combination like Tazobactam and piperacillin-
tazobactam. 
 
EXTENDED SPECTRUM BETA LACTAMASES - DETECTION 
METHODS  
SCREENING OF ESBL 
37,38,35,9,7
 
Disc Diffusion method
  
 As per CLSI 2018, zone size of Cefotaxime-≥27mm, Ceftriaxone-≥27, 
Ceftazidime-≥22mm, Cefpodoxime-≥17m and Aztreonam-≥27mm and 
showing resistant to more than 2 of 3
rd
 generation cephalosporin is considered 
screening test positive 
Phenotypic confirmatory disc diffusion test. 
 AS per CLSI guidelines, cefotaxime (30μg) and ceftazidime discs 
(30μg) with or without clavulanate (10μg) is used test to confirm ESBL 
production in Klebsiella species and there should be a difference in zone size of 
5mm between them 
 
Broth Micro dilution method
 
- 
 In Broth microdilution assays are done with ceftazidime (0.25 
to128μg/ml), ceftazidime with clavulanate (0.25/4 to128/4 μg/ml) combination, 
and cefotaxime (0.25 to 64μg/ml) with cefotaxime / clavulanate (0.25/4 to 64/4 
μg/ml). Decrease in MIC of ≥ 3 two fold in antimicrobial agent that was used 
in combination with clavulinic acid to the MIC of the drug tested alone will 
confirm ESBL enzyme. 
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COMMERCIAL METHODS -Epsilometer-Test for ESBLs 
 It is tested with a Plastic strips carrying ceftazidime (0.5μg - 32μg/ml) at 
one end and combination of ceftazidime plus clavulanic acid (0.064-4μg/ml) at 
another end in varying concentration gradient compared with with 
predetermined concentration of clavulanic acid (4μg/ml). The sensitivity is 87-
100% and the specificity asis 100%. ESBL production is confirmed by 8-fold 
reduction in the MIC of cephalosporin with clavulanate 
 
Vitek ESBL cards test An automated method which measureses the growth 
when certain threshold is reached. Here well showing reduced growth with 
drugs in combination with clavulanate is compared to growth with drug alone 
and is considered positive 
 
MOLECULAR METHOD 
DNA probes Specific gene for 
each family 
(e.g., TEM or SHV 
Labor demanding, difference between 
ESBLsand non-ESBLs, & TEM or 
SHV cannot be made out. 
PCR  Easy to carry out,  
 
difference between ESBLsand non-
ESBLs, & TEM or SHV cannot be 
made out. 
Oligotyping Variant specific, eg 
SHV 
 precise oligonucleotideprobes should 
be used, labor demanding, new variants 
are not identified 
PCR-RFLP Easy to carry out, 
detect exact changes 
in the nucleotide. 
Needs to detect the restriction site for 
changes 
Nucleotide 
Sequencing 
The gold standard,  
 
Labor demanding,  
Technically difficult  
interpret manual is also difficult 
Real Time 
PCR 
Qualitative & 
quantitative 
costlier, needs expert skill 
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AMPC RESISTANT
37,9,7
 
 AmpC ß-lactamase are resistance to cephamycins and ther are not 
susceptible to β lactam inhibitor. Inducible type of AMPC lactamases are 
usually chromosomally mediated and this kind of resistance are seen in 
Enterobacter cloacae, Citrobacter freundii, Serratia marcescens indole-
positive Proteus mirabilis. The other type is Plasmid mediated encountered in 
Escherichia. coli, Klebsiella specise, Salmonella species. and Proteus 
mirabilis. Genes responsible for Ampc resistant are ACC, FOX, MOX, DHA, 
CIT and EBC3-5. it is noted that Ampc enzyme showing porin mutation are 
prone for carbapenem resistance.Currently there are no CLSI recommended 
guidelines to detect Amp C beta lactamases. 
 
Detection of AmpC Beta Lactamase:
39,9,7 
 Cefoxitin(30µg) disk showing Zone of inhibition <14mm is considered 
screening for AmpC β Lactamase positive.  
 
Confirmatory Test f 
or AmpC Production- AmpC Disk Test : 
40,41, 42 
 Lawn culture of Escherichia coli ATCC 25922 on Mueller- Hinton agar 
is tested with Cefoxitin (30µg) disc and. saline moistened Sterile disks (6mm) 
with test organism inoculated onit and placed near it, and incubated, at 35ºC for 
16-18 hours. Flattening or indentation of the cefoxitin inhibition zone in the 
vicinity of the organism disc confirms AmpC production. 
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Combined disc diffusion test 
7 
 It uses combination of Cefoxitin 30μg disc with and without 
phenylboronic acid(30 μg) on to a muller hinton agar plate. A zone size of 
more than 5mm around the disc containing the combination of cefoxitinwith 
phenylboronic acid confirms AMPC production 
 
E-TEST 
7 
Ampc - strip is aplastic strip containing cefotetan on one side and cefotetan 
with cloxacillin on the other side. MIC ratio of ≥8 is considered as AMPC 
producers 
 
Detection of Co-Existence of ESBL & AmpC Production:
43,44 
 Fourth generation cephalosporin is recommended for this test. Though it 
is hydrolyed by ESBLs, it is not hydrolysed by Class C beta lactamases.  
 
Disk diffusion synergy test (DDST)  
 ceftazidime-clavulanate combination with four cephalosporins 
belonging to 3
rd
 generation cephalosporin like cefotaxime, ceftriaxone, 
cefpodoxime and cefepime are used. Any distortion or zone increasing towards 
the disc of ceftazidime-clavulanate from Cefipime disk (4
th
 Generation 
Cephalosporin) shows ESBL production along with AmpC coexistence  
 
MOLECULAR STUDY 
MULTIPLEX PCR 
 The “gold standard” test for identification of AmpC enzymes is 
Multiplex PCR. The most important plasmid mediated AmpC genes involved 
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are ACC, FOX, MOX, DHA, CIT and EBC (2) & koney Microarray assay is an 
epidemiological stool for detecting AmpC-resistant  
 
CARBAPENEM
45,46 9 
 The carbapenems are a group of beta-lactam antibiotics that carries 
carbon atom with added double bound in the beta lactam ring that differentiate 
it from pencillin 
 
 Serine carbapenemases present inrclass A and s ubgroup 2f β carry both 
of molecular classification carry both chromosomal as well as plasmid 
mediated resistance. They a are sensitive to tozabactam. while KPC 
carbapenemase are only plasmid mediated and easily capable of hydrolysis 
aminothiazoleoximecephalosporins, (cefotaxime). This is most noted in in 
Klebsiell. pneumoniae, and the variant KPC-1, was captured from 
NorthCarolina in 1996. While variant KPC-2 was notified from the east coast 
of theUnited States. KPC-2 are results of point mutation of KPC-1. 
 
 Serine carbapenemase belongs to class A and include genes like TEM-1 
and SHV-1, KPCs, OXY and ESBLs CTX-M types. Zinc based are Metallo-β-
lactamases and include gene like; VIM, IMP, SPM, NDM, GIM, SIM. 
Metallobeta lactamase are zinc carbapenemase that hydrolysis Carbapenems 
but not the, monobactams. Plasmid-encoded MBLs areIMP and VIM family 
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seen in Enterobactericeae family, Pseudomonas and Stenotrophomonas 
maltophilia.The MBLs families are VIM –indicates Verona integron, IMP 
substrate active for imipenem, GIM forGerman imipenemase enzyme, and SIM 
for“Seoul imipenemase”. These are present as gene cassettes included various 
integron structures. These integrons are easily transferrable between 
bacteriaThe transfer between bacteria with help o plasmids or transposons.first 
Transferable resistance in imepenem was seen Pseudomonas aeruginosa in 
Japan, in 1990. 
 
  From Klebsiella pneumoniae the first case of New Delhi metallo--
lactamase was reported in a Indian origin patient from sweden in 2008. (NDM-
1) are plasmid mediated and contain numerous determinants coding for 
multiple drug resistant. Inhibition by EDTA, dipicolinicacid and o-
phenanthrolin to carbapenase is noted, but they are not by inhibited by 
clavulanic acid.In india it is found to be endemic especially in the Balkans. 
Another type of betalactamase is OXA-48 specially seen in Acinetobacter and 
Pseudomonas 
DETECTION OF CARBAPENEMASE
7,9,45
 
Screening test 
Isolates showing zone size <22mm to Ertapenem(10µg) are said to be 
carbapenemase producer(DR6) 
 
Chromogenic media to screen for CPGNB 
49
 
Carbapenemase production is identified based up on the colour production. 
chromogenic media used are (i) Oxoid Brilliance ESBL (ii) Oxoid Brilliance 
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CRE, (iii) bioMérieux chromID Carba (iv) CHROMagar Colorex C3Gr, and 
(v) CHROMagar Colorex KPC.  
 
MODIFIED HODGE TEST 
 Meropenem(10µg) disc is placed in the Lawn culture of E.coli ATCC 
25922 on Mueller Hinton agar and inoculated.Test  strains  are  inoculated in a 
straight line from the edge of the disc (20-25mm length). Following incubation, 
enhancement or indendation of growth of indicator strains around meropenem 
is  taken as Modified Hodge test positive 
 
Combined Disc Diffusion Test 
7 
 Two imipenem(10µg) discs is placed on a Mueller Hinton agar plates 
inoculated with the organism.To one of the imipenem disc add 10µL of 0.5M 
EDTA (750µg) solution and incubate for 24hours at 37ºC. An difference in the 
zone of inhibition of at aleast 7mm between the imipenem-EDTA disc and 
imipenem alone was considered as positive result 
 
Detection of KPCs WITH Boronates 
7 
 Phenotypic detection of KPC production is based on the susceptibility of 
KPCs to boronic acid and its derivatives, i.e., phenylboronic and 3-
aminophenylboronic acid. boronates preferentially inhibit KPC-type -
lactamases.  
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NP carba test 
47, 35
 
 Acidimetric test where the beta lactam ring gets hydrolysed and as a 
result PH drops, indicated by color change from red to yellow.it is 
aconfirmatory test as recommended by CLSI 
 
PROCEDURE 
 Bacterial protein extract are added to two tubes marked 1 and 2.loopful 
of overnight bacterial growth from blood agar plate is added to both the 
tubes.vortex for five seconds. 100 μl of solution A is added to tube A and 100 
μl of solution B which contains imepenem with solution A is added is added to 
tube b vortex both the tubes and incubate at 37ºC the results are read within 2 
hours. 
 
Tube a containing solution 
A (control) 
Tube b Solution B 
(solution A+ imepenem) 
Results 
Colour remains the same Red 
or red orange 
No ccolour change. remain 
Red or red orange 
Carbapenemase is 
not detected test is 
Negative 
Red or red orange colour 
remains rhe same 
Show colour change either 
yellow or dark yellow or 
Light orange in colour 
carbapenemase is 
detected test is 
Positive 
Red or red orange colour 
remains the same 
Only Orange is produced  Test is not valid 
 Shows different colour 
change yellow, dark yellow 
Light orange or orange 
Any type of color may be 
noted 
 Test is not invalid 
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 Rapidec Carba NP test
90
 is available in which naked eye reading of the 
plate at 30 minutes and 2 hours are done 
 
MODIFIED CARBAPENEM INACTIVATION METHOD  
MEROPENEM DISK ACTIVATION TEST 
 To 2ml of tryptase soya broth add loopfull of bacterial culture votex for 
10 minutes. Place 10μg of Meropenem disc in it and incubate at37◦c for 4hours 
in ambient air.Make a lawn culture of ATCC E.coli and place the meropenem 
disk from the broth and incubate it at 37◦c for 24 hours. Carbapenemase 
production is indicated by zone diameter between 6-15mm orpin point 16-
18mm zone showing c olonies  
 
EDTA. MODIFIED CARBAPENEM INACTIVATION METHOD  
 2ml of trptase soya broth is added to two tubes separately. Innocualte 
the tubes with loop full of bacterial culture. Vortex for 10 seconds. To one tube 
place 10μg of Meropenem disc and to other tube place the meropenem disk and 
add20μL of 0.5 M EDTA to make it to a concentration of 5mmEDTA. Incubate 
it for 4 hours at at37◦c.Make a lawn cultureof ATCC E.coli on MHA plate and 
place both meropenem disk on it and incubati it for 24 hours at 37◦c. An 
increase in zone diameter of more than 5mm in eCIM when compared to zone 
size of CIM indicates metallobetalactamase is produced. This shows 
metallobetalactamase is produced but inhibited by EDTA. 
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Molecular Detection of Carbapenemase Genes  
METHODS ADVANTAGES 
Real time PCR  Accurate diagnosis is given by themelting curve step  
Multiplex PCR  Detects multiple carbapenemase gene  
Microarray Single reaction step and detects multiple gene 
Spectrophotometry Use crude or partially prepared enzyme and is the 
reference method  
(MALDI-TOF MS) Under high vaccum ionization of paticle take place and 
resutsare wt-ithin short time 
 
TREATMENT OF INFECTIONS WITH ESBL-PRODUCING 
5
 
ORGANISMS 
 In vitro susceptibility to cephamycins and carbapenems is seen with 
ESBLs producer. Though TEM and SHV type ESBLS, being susceptible to 
cefepime piperacillin/tazobactam in vitro isgeneral, they exhibit inoculum 
effect, showing decreased susceptibility, as the size of the inoculum is 
increased from 10
5
 to 10
7
 organisms. While CTX-M type and OXA type 
ESBLs are not inhibited by cefepime  
 
Inhibitor-Resistant B-Lactamases : The inhibitor-resistant TEM variants 
though susceptibleto inhibitory action of piperacillin/ tazobactam they are 
inhibited by the action of clavulinic acid and sulbactam 
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AmpC 
  The drug of choice for treating infection with AmpC –Producing strains 
are carbapenems group of drugs., but when associated with porin loss ther are 
vulnerable to show carbapenem-resistant as well. 
 
Carbapenemases  
 Strains possessing IMP- VIM- and OXA type gene s in general are 
susceptible to aztreonam, cloistin and polymixin B. 
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MATERIALS AND METHODS 
 
 The present study was conducted in Department of Microbiology, 
Government Kilpauk Medical College and Hospital, Chennai, India 
 
Study population:  
 A total of 800 patients with wound infection attending as outpatient and 
inpatient in Kilpauk Medical College and Hospital, Chennai were included in 
the study.  
 
Study period  
June 2017 to May 2018 
Study Design-Cross sectional study 
Samples was collected from both the sexes and from all age groups 
 
ETHICAL CONSIDERATION  
 The study was approved by our Institutional Ethical Committee and 
Ethical clearance was obtained  
 
STATISTICAL ANALYSIS  
 All statistical analyses were carried out using SPSS for Windows. Odds 
ratios (ORs) and 95% confidence intervals (CIs) were calculated. P values were 
calculated using the chi-square test. A p value of < 0.05 was considered 
significant.  
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INCLUSION CRITERIA
9,7
 
Specimen collected prior to initiation or therapy 
 Wounds that are clinically infected, detiorating and failing to heal over a 
long period of time 
 Viable wound tissues 
  All Klebsiella species isolates obtained from the wound infection. 
  
EXCLUSION CRITERIA 
 Specimen obtained after initiation of therapy. 
 Specimen from necrotic tissues 
 Drainage tube devices  
 
MATERIALS AND MEHTODOLOGY :  
Methodology Includes 
1. Collection of sample 
2. Identification of organisms by standard Microbiological test  
3. Antibiotic sensitivity pattern by kirby bauer disk diffusion method 
4. Isolation of Resistant strains by screening test 
5. Confirmatory test to Detect ESBL, AmpC and Carbapenemase 
production among Klebsiella species isolated 
6. Identification of Carbapenem resistant gene by molecular method. 
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SPECIMEN COLLECTION; 
collection of specimens:
4
 
7,9,34 
1. pus:  
 The area over the abscess was wiped with sterile saline or 70% alcohol 
and pus was aspirated and collected in a sterile test tube.  
 
2. swab:  
 After cleaning the wound area with sterile saline samples were collected 
by rolling the swab on the infected surface by applying slight pressure covering 
an area of 1cm. Two swab specimens was collected, one for smear examination 
and one for culture.  
 
SPECIMEN PROCESSING:
7,9,4
 
DIRECT MICROSCOPY 
 The swabs was received in duplicate. One swab was used for gram 
staining. It was observed for pus cells and Gram negative & positive bacteria. 
And squamous epithelial cells 
 
CULTURE 
 The specimen was inoculated on Blood agar plate, Macconkey plate and 
Nutrient agar plate. The plates was incubated at 37◦c for 18-24 hours. 
 
Plates were examined for 
 Blood agar: Non hemolytic colony 
 Macconkey agar : Lactose fermenting mucoid colonies 
 Nutrient agar. Large doom shaped Greyish white mucoid colonies 
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 The suspected Klebsiella isolates were chosen from their colony 
morphology for further testing. 
 
 Gram staining from the colony smear 
 It was observed for Gram negative short rods with parallel sides and 
rounded edges with capsule around them 
 
 String test  
 It was observed for the formation of viscous string of>5mm, when 
mucoid colonies from from macconkey agar was lifted with a loop. 
 
 Motility test 
 Motility of the organism was tested by hanging drop method. Non 
motile rods were observed. 
 
Speciation of klebsiella was done by standard biochemical reaction 
 Klebsiella 
pneumoniae 
Klebsiella oxytoca 
Hugh – leifson oxidation - 
fermentation  
fermentative fermentative 
Nitrate reduction test reduced reduced 
Indole test positive negative 
Voges-proskauer test positive positive 
Methy red test negative negative 
Citrate utilization test  Positive Positive 
Triple sugar iron agar test Acid/acid with gas Acid/acid with gas 
Urease test hydrolysed hydrolysed 
Mannitol motility test Fermented/non motile Fermented/non motile 
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ANTIBIOTIC SENSITIVITY15as recommended by CLSI 2018
35,9,7
 
Preparation of inoculum and inoculation: 
 Isolated Klebsiella species colonies from nutrient agar was inoculated in 
to a test tube containing 1.5ml of Nutrient broth and incubated for 2 hours. Its 
density was compared with 0.5 Mcfarland’s standard which corresponds to 150 
million organism per ml. A sterile cotton wool swab was dipped into the 
suspension and excessive fluid is drained of by turning round the swab along 
the side of the tube.Then a lawn culture was made on a MHA plate. After 5 
minutes antibiotics as per guidelines was placed. They include  Amikacin 30 
μg, Gentaamicin 10 μg, Ciprofloxacin 5 μg, trimethoprim – sulphomethaxazole 
1.25 μg/23.75 μg, cefotaxime 30 μg, ceftazidime30 μg, cefoxitin30 μg, 
Cefepime30 μg, Meropenem 10 μg, piperacillin/tozabactum 100/10 μg. 
Resistant strains were identified by following methods 
 
 
Screening for ESBL
9,7
 
 Isolate showing inhibition zone of ≤ 22mm for Ceftazidime (30µg), 
and≤ 27mm for Cefotaxime (30µg) was taken as positive and subjected for 
Confirmatory test.  
 
 
 glucose sucrose lactose mannitol mannose lysine ornithine arginine 
KP + + + + + + _ _ 
KO + + + + + + _ - 
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Confirmatory Test for ESBL:
35
 
Phenotypic disk confirmatory test CLSI 2018 
 Ceftazidime (30µg) and Ceftotaxime with without Clavulanic acid 
(30µg/10 µg). disks wasplaced at least 20 mm apart, on a Mueller- Hinton agar 
plate streaked with test isolates and incubated overnight at 37ºC. A zone 
difference of ≥5mm around Ceftazidime and Ceftazidime with Clavulanic acid 
was taken as ESBL positive
 
 
E-STRIP TEST
35
 
 Muller hinton agar plate streaked with test organism and An E-strip 
containg a concentration gradient of ceftazidime (0.5μg - 32μg/ml) and 
ceftazidime plus clavulanic acid (0.064-4μg/ml), was placed on it and 
incubated at 37 c for 18-24hrs. 
 
 MIC of ceftazidime / ceftazidime-clavulanate ratio ≥ 8 indicated the 
presence of ESBL isolates  
 
Screening for Ampc 
7,9.35
 
 All the Klebsiella pneumoniae isolates were screened for AmpC β 
Lactamase using cefoxitin(30µg) disk. Isolates showing resistant to cefoxitin 
(ie., Zone of inhibition <14mm) was considered as positive for AmpC β 
Lactamase. Screened positive isolates were further confirmed by AmpC disk 
test 
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Confirmatory Test for AmpC Production- AmpC Disk Test 
40,41, 42 
  To the lawn culture of Escherichia coli ATCC 25922 on Mueller- 
Hinton agar, Cefoxitin(30µg) disc was placed on it. A sterile disks (6mm) 
moistened with sterile saline (20µl) and inoculated with several colonies of test 
organism,was placed beside almost touching the cefoxitin dis and incubated at 
35ºC for16-18 hours. Flattening or indentation of the cefoxitin inhibition zone 
in the vicinity of the test organism disc was taken as positive for AmpC 
producers. 
 
Detection of Co-Existence of ESBL & AmpC Producers. 
43,44 
 Disk diffusion synergy test (DDST)  
 Ceftazidime-clavulanate disc was placed in the centre of lawn culture of 
the organism on Mueller-Hinton agar plate. Then cefotaxime, ceftriaxone, 
cefoperazone and cefepime discs were placed 15 and 20 mm apart 
respectively,. Any distortion or increase in zone towards the disc of 
ceftazidime-clavulanate from Cefipime disk (4
th
 Generation Cephalosporin) 
was considered positive for ESBL production with coexistence of AmpC
  
 
Detection of carbapenamase resistance:CLSI
35
 
 Isolates showing resistance to Ertapenem(10µg) with zone size of less 
than 17 mm was takem as positive and further tested for phenotypic 
confirmation methods.
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MODIFIED CARBAPENEM INACTIVATION METHOD 
35,47,48
 
Modified carbapenem inactition test 
 To 2ml of tryptase soya broth add loopfull of bacterial culture votexed 
for 10 minutes. 10μg of Meropenem disc was placed in it and incubated at37◦c 
for 4hours in ambient air. To the lawn culture of ATCC E.coli, the meropenem 
disk from the broth was placed and incubated at37◦c for 24 hours. zone 
diameter between 6-15mm or pin point 16-18mm zone showing colonies was 
taken as carbapenemase producer.  
 
E-strip 
35 
 Strip containing imepenem on one end and imepenem with EDTA was 
placed on a MHA plate and incubated for 24 hrs MIC of >8 was taken as 
positive 
 
MOLECULAR METHOD  
 Bacterial DNA minispin purification kit. Kit contains Lysozyme, 
Lysozymedigestion buffer, Proteinase-K, Binding buffer, Wash Buffer-1, Wash 
Buffer-2, Spin columnswith collection tube and elution buffer. 
 
2X Master Mix: 
It includes 2U of Taq DNA polymerase, 10X Taq reaction buffer, 2mM 
MgCl2, 1μl of 10mM dNTPs mix and RedDye PCR additives. 
 
Agarose gel electrophoresis: 
Agarose, 50X TAE buffer, 6X gel loading buffer and Ethidium bromide are 
from HELINI Biomolecules, Chennai. 
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PCR: 
PCR Product: 387bp Helini ready to use VIM gene Primer mix - 5μl/reaction 
PCR Product: 125bp Helini ready to use NDM gene Primer mix - 5μl/reaction 
PCR Product: 202bp Helini ready to use KPC gene Primer mix - 5μl/reaction 
 
Bacterial DNA Purification 
 Centrifuge 1ml of culture at 6000rpm for 5min and discard the 
Supernatan. Suspend the Pellet in 0.2ml PBS add 180μl of Lysozyme digestion 
buffer and 20μl of Lysozyme [10mg/ml] and Incubated it for 15 min at 37C. 
Add 400μl of Binding buffer, 5μl of internal control template and 20μl of 
Proteinase K and Mix well.After Incubating it at 56ºC for 15mi,add 300μl of 
Ethanol and mix well. Transfer into the PureFast® spin column and Centrifuge 
it for 1 min. The flow-through is discarded after washing with a 500μl Wash 
buffer-1 buffer -2 by Centrifuge for 30-60 seconds each time and discard the 
flow-through. Place the column back into the same collection tube Discard the 
flow-through and centrifuge for an additional 1 min. Now add 100μl of Elution 
Buffer to it and Incubate for 1 min at room temperature and again centrifuge 
for 2 min.The purified DNA is stored at -20°C. Quality and Quantity of 
extracted DNA is checked by loading in 1% agarose gel and 5μl of extracted 
DNA isused for PCR amplification 
 
PCR Procedure: 
 HELINI RedDye PCR Master mix 10μl, Ready to use - Primer Mix 5μl 
and Purified mix Bacterial DNA 5μl to make it to a make up a volume of 20μl. 
 54 
 
Run thePrograme st. Denaturation sets in at a temperature of 95ºC for 5 min 
and 94ºC for 30sec followed by Annealing at a temperature of 58ºC for 30sec 
for 35 cycles. Initial extension starts at at a temperature of 72ºC for 30sec and 
Final extension for a period 5 min at 72 ºC 
 
Agarose gel electrophoresis: 
  To 2% agarose add 5μl of Ethidium bromide at 60ºC temperature. It 
ispoured into the gel plate and allowed for solidification. gel plate is then 
placed in a tank filled with 1XTAE buffer 
 
 Samples from PCR are loaded, after mixing with gel and loading dye 
along with 10μl HELINI100bp DNA Ladder. [100bp, 200bp, 300bp, 400bp, 
500bp, 600bp, 700bp, 800bp, 900bp,1000bp and 1500bp] now the 
electrophoresis is runned at 50Vun till the dye moves upto three fourth distance 
in the gel plate. band pattern produced by them are viewed by placing it 
beneath the under UV Transilluminator. 
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RESULTS 
 
Specimens obtained from patients with wound infection attending OP and IP 
Govt Kilpauk Medical College and Hospital were studied from June 2017 to 
May 2018 to identify the bacteriological profile, to isolate Klebsiella species, to 
find its antimicrobial susceptibility pattern, to find the incidence of ESBL, 
AMPC and Carbapenem producing Klebsiella species among them. As Kilpauk 
medical college are superspecialized in managing burns injury, and as surgical 
site infection is the most common wound infection globally, higher number of 
patients were included from these two units. Wound swabs and pus were taken 
from 800 patients which includes 300 from burns wound infection, 300 from 
surgical site infection, 100 from diabetic ulcer patients and 100 from abscess 
and pressure ulcer. 
Table -1 : Age distribution n=800 
Age Total no Percentage 
1-20 123 15.37% 
21-40 268 33.5% 
41-60 291 36.37% 
61-80 111 13.87% 
81-90 7 0.87 
 
 Maximum age group were from 41-60years (36.3%) and 21-40(33.5%) 
years  
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Table 2 : SEX DISTRIBUTION N=800 
Woundd distribution Male female 
Burns wound n=300 125(41.6%) 175(58.33% 
Surgical site infection n=300 174(58%) 126(42%) 
Diabetic ulcer n=100 79(79%) 21(21%) 
Abscess & pressure ulcer n=100 69(69%) 31(31%) 
Total n=800 447(55.87) 353 (44.1 
 
Among 800 samples 447(55.87%) were males and 353(44.1%) were female 
Chi square 53.79 & P-value <0.05 i.e significant 
 
Table -3 CULTURE POSITIVE N=800 
Culture positive 394 49.25% 
Culture negative 406 50.75% 
Culture showing bacterial growth was 49.5% 
 
Table - 4 DIRECT GRAM SMEAR Vs CULTURE POSITIVE N=800 
 Direct gram smear positive Direct gram smear negative 
Culture positive 376(47%) 18(2.25%) 
Culture negative 9(1.12%) 397(49.62%) 
 
Both culture and gram smear positive were 47%&2.25%.Culture negative and 
gram smear negative were 1.12%&49.62%. Chisquare value 695.94. P- value 
<0.05% i.e significant. 
Chart -1 SEX DISTRIBUTION 
 
 
CHART - 2 Culture positive isolates 
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Table 5: MONOMICROBIAL VERSUS POLYMICROBIAL N=394 
Monomicrobial 293 74.36% 
Polymicrobial 101 25.63% 
 
Among 394 growth 293(74.36%) were monomicrobial and 101(25.63%) were  
Polymicrobial 
 
 
TABLE -6 GRAM NEGATIVE BACILLI verses GRAM POSITIVE COCCI 
(Monomicrobial n=293) 
Gram positive bacteria 98 33.44% 
Gram negative bacilli 195 66.55% 
Gram negative bacteria was 66.55% and Gram positive bacteria was 33.44% 
 
Risk factors In burns maximum patients presented with 21-40% (65.5%) of 
TBSA. In surgical site infection maximum growth were seen in post operative 
patients( 66.66%) than in preoperative patient In diabetic ulcer patients with 
longer duration of diabeties of more than 10 years and patients with poor poor 
glycemic control (57.14%) showed maximum growth. 
 
 
 
 
 
CHART -3 Monomicrobial versus Polymicrobial 
 
 
 
CHART-4 Gram negative bacteria verses Gram positive bacteria 
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DISTRIBUTION OF ORGANISM IN VARIOUS DEPARTMENT  
Table- 7 Monomicrobial n=293 
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Burns 
(n=159) 
21 
13.20% 
6 
3.77% 
2 
1.25% 
14 
8.80% 
29 
18.23% 
2 
1.25% 
4 
2.51% 
27 
16.98% 
54 
33.96% 
Surgery 
(n=132) 
26 
19.6% 
4 
3.03% 
7 
5.32% 
23 
17.42% 
17 
12.87% 
1 
0.75% 
4 
3.03% 
20 
15.15% 
30 
22.72% 
Diabeticulcer 
(n=57) 
13 
22.80% 
- - 5 
8.77% 
10 
17.59% 
3 
5.26% 
3 
5.26% 
11 
19.29% 
12 
21.29% 
Abscess& 
pressureulcer 
(n=46) 
17 
36.95% 
 
- 
2 
4.34% 
12 
26.08% 
6 
13.04% 
1 
2.1% 
 
- 
3 
6.52% 
5 
10.86% 
 
total 
77 
26.27% 
10 
3.41% 
11 
3.75% 
54 
18.43% 
62 
21.16% 
7 
2.38% 
11 
3.75% 
61 
20.81% 
101 
25. 63% 
Klebsiella species were the predominant organism (18.2%) in burns patients.In 
surgical site diabetic, ulcer abscess and pressure ulcer, staphylococcus aureus 
were the predominant organism. Chisquare value 52.5% P- value <0.05% ie.it 
is significant 
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Table -8 KLEBSIELLA SPECIES ISOLATED FROM DIFFERENT 
SPECIMEN 
 Klebsiella 
pneumoniae 
Klebsiella 
oxytoca 
Total 
Burnswound (N=159) 62 4 66(41.67%). 
Surgical site infection 
(N=132) 
24 3 27(21.25%) 
Diabetic ulcer (N=57) 11 3 14(24.56%) 
Abscess& pressure ulcer 
(N=46) 
6 0 6(13.04%%) 
TOTAL(394) 103(26.14%) 10(2.53%) 113(28.68%) 
 
 Klebsiella pneumoniae isolated from burns wound infection (41.67%). P 
value by chisquare is 0.012 ie it is significant 
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Table- 9 Antimicrobial Susceptibility pattern of Klebsiella species isolated 
 Klebsiella 
pneumoniae 
N=103 
Klebsiella oxytoca 
N=10 
Amikacin 72(69.9%) 6(60%) 
Gentamicin 67(65.04%) 5(50%) 
Co-trimoxazole 22(21.35) 0 
Ciprofloxacin 49(47.57%) 1(10%) 
Cefotaxime 37(39.51%) 2(20%) 
ceftriaxone 48(46.31%) 3(3o%) 
Ceftazidime 53(50.03%) 4(40%) 
Amoxicillin-clavulinic acid 66(64.07%) 3(30%) 
Cefoxitin 80(77.6%) 5(50%) 
Cefipime 71(68.93%) 4(40%) 
Meropenem 89(86.40%) 10(100%) 
Piperacillin-tozabactam 84(81.5%) 7(70%) 
  
 Klebsiella pneumoniae and Klebsiella oxytoca shows maximum 
sensitivity to Meropenem 86.40% & 100% & Piperacillin - Tozabactam 81.5% 
& 70%, least sensitivity Co-trimoxazole 21.35% & 0% and Ciprofloxacin 
47.57% & 10% respectively. No resistant strain was detected in Klebsiella 
oxytoca 
 
 
CHART- 5 Speciation of Klebsiella from various department. 
 
 
CHART - 6 Antimicrobial Susceptibility pattern of Klebsiella species isolated 
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Table 10 ESBL DETECTION IN KLEBSIELLA PNEUMONIAE ISOLATES 
 Screening Confirmatory 
 screening % PDCT E-STRIP % 
Burns N=66 36 54.54 31 31 46.96 
Surgery N=27 13 48.14 10 10 37.03 
Diabetic N=14 7 50 6 6 42.85 
Abscess & pressure 
ulcer N=6 
1 16.1 - - - 
 Maximum ESBL production was seen in burns wound infection 46.96% 
by confirmatory test.  
 
Table-11 AMPC DETECTION IN KLEBSIELLA PNEUMONIAE ISOLATES 
 Screening 
Confirmatory 
Ampc disk test Total % 
 Total no % Total no 
Burns wound (n=66) 14 21.21% 11 16.6% 
Surgical site infection 
(n=27) 
6 22.92 5 18.51 
Diabetic ulcer (n=14) 2 14.28% 2 14.28 
Abscess & pressure ulcer 
(n=6) 
- - - - 
 Ampc production by Klebsiella species in surgical site infection 
(18.51%) was maximum.  
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Table 12 CO-EXISTENCE OF ESBL& AMPC BY AMPC DISK TEST IN 
KLEBSIELLA PNEUMONIAE ISOLATED 
Burns wound 
n=66 
Surgical site 
infection 
n=27 
Diabetic 
ulcer 
Abscess & pressure 
ulcer 
TOTAL 
N=113 
3(4.5%) 2(7.4%) - - 5(4.42%) 
 
 Co-Existence of ESBL & AmpC in burns wound was (4.5%) and in 
surgical site infection was (7.4%) 
 
 
TABLE-13 : TOTAL ESBL AND AMPC DETECTION IN KLEBSIELLA 
SPECIES ISOLATED 
 ESBL AMPC 
Burns wound(N=66) 34(51.51%) 14(21.21%) 
Surgical site infection(N=27) 12(44.44%) 7(25.92%) 
Diabetic ulcer(N=14) 6(42.85%) 2(14.28) 
Abscess & pressure ulcer (n=6) - - 
Total N=113 52(46.01%) 23(20.35%) 
 
 Total ESBL production in wound is 46.01% a nd AMPC production is 
20.35% 
 
 
CHART-7- Co-existence of Esbl & Ampc in Klebsiella pneumoniae isolates in 
various departments 
 
 
 
CHART - 8 Distribution of ESBL AND AMPC producing Klebsiella 
pneumoniae in various departments 
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TABLE 14 : CARBAPENEMASE DETECTION IN KLEBSIELLA 
PNEUMONIAE ISOLATES 
 
SCREENING 
TEST 
CONFIRMATORY TOTAL% 
 NO % MCIM E-TEST Total % 
Burns wound (n=66) 9 13.63 8 8 12.1% 
Surgical site infection (n=27) 4 14.81 1 1 3.7% 
Diabetic ulcer (n=14) 1 6.25 o - - 
Abscess & pressure ulcer (n=6) - - - - - 
TOTAL N=113 14 12.38% 9 9 7.96% 
 
 Maximum MBL production was seen in burns wound infection (12.1%) 
 
Table 15 MOLECULAR STUDY OF CARBAPENEMASE PRODUCING 
KLEBSIELLA PNEUMONIAE 
 blaNDM blaKPC bla IMP 
Klebsiella pneumoniae 9 - - 
 
Table 16 Molecular study of co exsisting ESBL & AMPCgene along with 
MBL producing Klebsiella pneumoniae 
N=9 MBL N=1 MBL & Esbl N=4 
MBL & AMPC 
N=4 
Carbapenem 
resistant 
Klebsiella 
pneumoniae 
blaNDM 
blaNDM and 
(blaSHV,blaTEM,&bla CTX) 
blaNDM & bla 
AMPC 
CHART - 9 Carbapenemase producing Klebsiella pneumoniae isolated in 
various department 
 
 
CHART -10 Co existence of ESBL, AMPC and MBL in Klebsiella 
pneumoniae 
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 Out of 9 MBL producers 4 cases were both MBL and Esbl producer, 4 
cases were MBL and AMPC producer and one was only MBL producer. All 9 
carried bla NDM gene, all 4 ESBL carried blaSHV, blaTEM, & bla CTX.4 
AMPC showed showed Ampc gene positive. 
 
Table 17: SENSITIVITY PATTERN OF ESBL, AMPC & MBL 
PRODUCING KLEBSIELLA PNEUMONIAE. 
DRUGS ESBL (n=52) AMPC (n=23) MBL (n=9) 
Amikacin 38(73.07%) 15(65.21%) 6(66.5%) 
Gentamicin 32(61.53%) 13(56.52%) 4(44.4%) 
Ciprofloxacin 9(18%) 4(17.39%) 2(22.2%) 
Cotrimoxazole 1(2%) 1(4.3%) 0 
Cefotaxi me 0 0 0 
Ceftazidime 4(7.6%) 3(13.04%) 2(22.2%) 
Ceftriaxone 4(7.6%) 2(7.4%) 3(33.3%) 
Amoxcillin-clavulinic acid 36(69.2%) 0 2(22.2% 
Cefoxitin 40(76.2%) 0 5(55.5) 
Cefipime 38(73,07%) 14(60.86%) 4(44.4) 
Meropenem 46(96%) 21(91.30%) 0 
Piperacillin-tozabactum 48(92.3%) 7(39.13%) 6(55.5) 
 
 Among ESBL & AMPC maximum sensitivity were shown to 
Meropenem 96% & 91.3% lower sensitivity to cotrimoxazole 2% & 4.3%. 
CHART-11 
 
 
 
 
 
 
38
32
9
1 0
4 4
36
34
32
46
48
15
13
4
1 0
3
1 0 0
14
21
76
4
2
0 0
2 1 2
4 4
0
6
0
10
20
30
40
50
60
Sensitivity pattern of ESBL, AMPC  AND MBL 
producing Klebsiella pneumoniae
ESBL(n=52) AMPC( n=23) MBL( n=9)
 65 
 
Carpapenamase showed maximum sensitivity to Amikacin 66.6% and least 
sensitivity to cephalosporins, cotrimoxazole and ciprofloxacin. 
 
All the MBL were susceptible to colistin. 
Outcome of the patients 
 In burns 13 case expired all of them carried the resistant strains 7 were 
MBL strain, 4 ESBL, 2 case of ampc& esbl. In Diabetic foot ulcer 3 cases were 
amputated all the 3 carried Esbl strains. In surgery 2 cases carrying esbl strain 
went in for sepsis and recovered.  
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DISCUSSION 
 
 As wound infection causes break through in the integrity of the skin they 
are vulnerable to the invasion of pathogenic microorganism with ensuing 
wound infection. The control of wound infections is foremost important in 
avoiding extensive spread of bacterial resistance to antibiotics. In the present 
situation, the existence of multi drug resistant (MDR) organisms and their 
spread is of immense concern particularly in wound infection. The survival of 
multiple beta lactamases among Klebsiella pneumoniae not only confines the 
therapeutic options but also impose a diagnostic challenge to the 
microbiologist. It is the duty of clinical microbiological laboratory to do routine 
screening and confirmatory test for ESBL, AMPC & MBL detection for 
effective treatment and controlling the development of further wound 
complications. 
 
 Out of 800 wound specimen received in the microbiology laboratory, 
300 was from burns wound infection, 300 from surgical site infection, 100 
from diabetic ulcer and 100 from abscess and pressure ulcer were included in 
the study. 
 
          The most common age group presented with wound infection were 
between 41- 60(36.3%) years and 21-40(33.5%) years which is similar to the 
study done by pooja singhet al
22
 and vikrant negi et al
51 
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 In the study male patients (55.87%) dominated female patient (44.1%) 
in surgical site infection and diabetic wound infection, which is similar to the 
study done by Gayathree naik et al
50
 and Vikrant negi et al
51
 and Ramya katee 
et al
52
. In burns wound female (58.33%) preponderance was seen in the study 
which was similar to the study done by latika sharma et al
53 
with female (56%) 
preponderance. Female preponderance may be due to the fact that they are 
more exposed to fire works 
 
 Total culture positive was 49.5% and culture negative was 50.75%. In 
concordance with the study Pooja singh et al
22
 showed lower growth rate of 
39% (culture positive), Contrary to the study vinitha et al
57
 showed a growth 
rate of 66.7%, kalpesh et al showed 95% and Gayatree naik et al showed72% 
culture growth. This lower percentage of growth rate may be due to the fact 
that most of the ulcer could have been superficial in nature at the time of 
sampling and also due to varied geographical location. 
 
  In the study 376(47%) direct Gram smear positive and 18(2.25%) Gram 
smear negative were culture positive. 397(49.62%) direct Gram smear 
negatives and 9(1.12%) Gram smear positive were culture negative. This is 
similar to the study done by Sameer et al
54
, Chenna Krishna
55
 and Ana 
kaftandieva et al 
56
 were they have stated that smear positive with culture 
negative may be due to presence of anaerobic bacteria which would have died 
on exposure to oxygen or bacterial contamination that had failed to multiply in 
wounds and also due to the presence of non viable organism.  
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 Most of the growth was monomicrobial 293(74.36%), and polymicrobial 
was 101(25.63%). This is similar to the study done by mohanasundaram
59
 were 
monomicrobial was 82.3% and polymicrob ial was 33.8%. sapna et al
60
 showed 
71. 8% as monomicrobial. There is considerably lower probability of wound 
healing when the invading bacteria belongs to more than 2 bacterial groups 
within a wound infection and this points out that intermicrobial communication 
would end up in worse pathogenic effect. The same was documented by 
Sharma S et al in his study.  
 
 In the study 98(33.44%) was gram positive bacteria and 195 (66.55%) 
were Gram negative bacteria. This study shows Gram negative bacteria to be 
the pre dominant isolate and it correlated with the study done by Narinder 
kaur
62
 were Gram negative bacteria was85% and 14.9% were Gram positive 
bacteria. In Abdul Rahim khan et al 
63
 Gram positive cocci were 36.4% and 
Gram negative bacilli was (63%)  
 
  The total body surface area involved in burns wound was 43(65.15%) 
from 21% to 40% of burns and 10(15.5%) from 41% to 60% burns and 4 
(6.06%) from 61 to 80% of burns. As per Kaur et al
62
, the risk of burns wound 
infection directly correlates with the extent of the burn. Thus the 4 cases with 
high percentage of burns in the study had polymicrobial wound infection. Most 
of them harboured resistant strains and had a fatal outcome. 
 
 In surgical site infection post operative patients (66.66%) showed 
maximum growth than preoperative stay contrary to our study kalpesh Hshah
58
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showed infection rate to be higher in patients with longer pre operative stay.this 
might be due to the fact that wound infection resulting from surgery exposes 
the raw area which provides good nourishment to the invading bacteria from 
the environment. 
 
 Maximum bacterial growth in Diabetic wound infection were seen in 
patient with longer duration of diabeties of more than 10 years and with poor 
glycemic control (57.14%). 3 cases amputated in the study belong to this group 
they showed poly microbial growth and harboured the resistant strain This is 
clearly evident in the study done by ramya kateel et al
52
. 
 
 In the study Staphylococcus aureu (26.27%) was the predominant gram 
positive organism isolated and in Gram negative bacteria predominant 
organism was Klebsiella pneumoniae 21.16%(62) followed by Pseudomonas 
aeruginosa 20.81%(61) and Escherichia coli 54(18.43%). This is similar to the 
study done by Naveen et al
64
 were Staphylococcus aureus(55.56%) was the 
predominant organism. Also in K Sharma et al
65
 study staphylococcus aureus 
(38%)was the predominant organism, But Sandeep kokate et al
66
 16%& Shoba 
et al et al
67
(43%) showed Pseudomonas as the commonest among gram 
negative bacilli isolated.Contrary to our study shreeram et al
68
 had showed E. 
coli (29.5%) to be the predominant organism.Variation in distribution of 
organism in various studies is due to different geographical location. 
 
 Total Klebsiella species isolated in the study was 113(28.68%). out of 
which 103(26.14%) was Klebsiella pneumoniae and 10(2.53%) were Klebsiella 
oxytoca.  
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 Most commonly isolated species was Klebsiella pneumoniae 
subspeciesaerogenes, name aerogenesSubspecies is no longer included in the 
approved list of bacterial names and for convenience purpose it is calles as 
Klebsiella pneumoniae
9 
 
 In burns 66(41.67% ) Klebsiella species were isolated, which is similar 
to the study done by khulood et al
69 
were 45.23% of Klebsiella pneumoniaewas 
isolated. Sharma S
61
, Sapana.g. Mundhada et al
60
 & Shanker Srinivasan et al
71
 
showed more than 33% of Klebsiella species growth.Contrary to our study Naz 
parween
72
 had isolated 22.08% of Klebsiella species, Narinder kaur et al 
62
 
showed 14.9% of Klebsiella pneumoniae and 8.7% of Klebsiella oxytoca and in 
Vimal rathod et al
73
 klebsiella oxytoca was (1.88%) & Klebsiella pne umoniae 
were 13.87%. Srinivasan et al
71
 in his study has given a data from 1991 to 
2000, the rate of isolation Klebsiella species to be more than 42%. This shows 
increased prevalence of Klebsiella species in wound infection, this may be due 
to the fact that strong virulence factor possed by them 
 
 In surgical site infection in the study Klebsiella species isolated were 
27(21.25%) which is similar to the study done by Patel S et al
24
 (21.4%), Neetu 
etal
74
(25.04%),Chenna krishnaetal
55
(26.37%) and Naveen kikkeri et al
64
 
(27.78%) while Amaradeep et a showed18.18% 75 andpooja et al
22
 showed a 
lower percentage of 3.5%. 
 
 In diabetic foot ulcer present study shows14(24.56%) Klebsiella species 
isolation. which is concordance with study done by jaain manisha etal
76
 
22.29% and Mehata VJ et al 
77
22%. Contrary to the study Ami varaiya etal 
78
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has showed a higher percentage of isolation of Klebsiella species 59.70%. 
While zubair et al
26
 showed a lower percentage of 9.2%, Anandhi et al
79
 
showed 13.6% and in bansal et al
80
 Klebsiella pneumoniae 17% & 4% 
Klebsiella Oxytoca was isolated in diabetic ulcer. 
 
 In pressure ulcer about 13.04% of Klebsiella species was isolated in this 
study.  Patel vk et al 
81
 isolated 11% of klebsiella species. In Ajay lunawal et al 
82
the prevalence of Klebsiella species was 18% and Ali.N. Dana et al
83
 found 
4% Klebsiella species in pressure ulcer. 
 
 The antibiotic sensitivity pattern of Klebsiella pneumoniae and 
Klebsiella oxytoca in the study showed maximum sensitivity to Meropenem 
86.40 % & 100%, to Piperacillin- Tozabactam it was 81.5% & 70%, Amikacin 
69.9% & 60% and Gentamicin 65.04%& 50%. This is similar to the the study 
done by jaspal kauretal
84
, sensitivity to Amikacin 92.4%, Gentamicin 86.4%, 
Piperacillin- Tozabactam100% and Meropenem100%. Shankar srinivasan et al 
71
 sensitivity for Piperacillin- Tozabactam was 77.4%, Meropenem 72.4% and 
Amikacin 66.9% and Naz perween et al 
72 
10% Meropenem, 26% piptaz 84%, 
and 60 % gentamicin to be resistant.
 
 
  In the study sensitivity to cefepime by Klebsiella pneumoniae and 
Klebsiella oxytoca was 68.93 % & 40%. Among the three third generation 
cephalosporin the least sensitivity was to cefotaxime (39.51% & 20%). 
Maximum resistant was shown for cotrimoxazole 21.35% & 0% and Amox- 
clavullenic acid 64.07% & 30% This is concordance with the study done by 
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Gaurav dalela et al
85
 sensitivity to cefepime 32.4%, amoxicillin with clavulenic 
acid 18.7%, cotrimoxazole 16.6% and vikrant et al 
51
 resistant to Amox-
clavullenic acid 100% and Neetu shree et al,
74
the resistant to Amikacin 41% , 
Piperacillin-tozabactum 47%  and Meropenem15%. In Chakroborthy et al
86
 the 
resistant shown to ciprofloxacin by Klebsiella pneumoniae and Klebsiella 
oxytoca were 37.5% & 50%. In the study ciprofloxacin resistant was 47.5% 
and 10% respstively. 
 
 In the study Klebsiella oxytoca did not produce any resistant strain. 
 
 In the study only ESBL producing Klebsiella pneumoniae was identified 
by screening test and confirmed by phenotypic disk conformatory method and 
E-test. In burns wound infection 36(54.54%) Klebsiella pneumoniae was 
screened for ESBL producers. Both the Confirmatory method showed 
31(46.96%) for only ESBL production.Total ESBL production including 
ESBL, detected from co existence of AMPC in Klebsiella pneumoniae in the 
study was 51.51%. This is similar to the study done by mundhawa
70
 showed 
51.6%. but various studies had shown either a higher or lower percentage. 
Begam fouza
87
 had showed a very higher percentage of ESBL 90.13%, by JB. 
Sharma et al
88
 it was 67%, loovera obero iet al 
89 
64.1% & vimal s. rathod
73
 it 
was 64.12%. Lower percentage was shown by.narinder kaur et al 
62
26.3% , 
Varsha gupta et al
43
 showed 20% and chamma
67
 et al 9%of ESBL production 
by Klebsiella pneumoniae in burns infection. 
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 In surgical site infection ESBL production in Klebsiella pneumoniae by 
screening test was 13(48.14%) and 10(37.03%) were confirmed by both 
conformatory method. Total ESBL production along with co exsistence of 
AMPC in Klebsiella pneumoniae in the study was 44.44%. This correlates with 
the study done by gadapalli et al 
91
were 44.7% was ESBL. Contrary to the 
study jacoby et al 
92
 showed 25 to 40%, Neetu shree et
74
 and amirtha shriyan et 
al 
93
 showed 74.9% & 75% respectively and loveena oberoi etal 
89 
ESBL in 
Klebsiella pneumoniae was 60% 
 
 In diabetic ulcer, ESBLproduction in Klebsiella pneumoniae by 
screening test was 7(50%) and confirmatory test it was6(42.85%) This 
correlates with the study done by Diwan mahamood khan 
94
 42.8% ESBL in 
diabetic ulcer, kavita et al 
95
46.72%, priyadarshini etal
96
 showed 40%. while 
higher percentage of ESBL production was shown by variya et al
97
 51.1%, 
sudhir k. jain
98
 et al 53% &deepaet al
99
 ESBL in diabetic ulcer was 50%. 
 
 Confirmation of ESBL production by clavulunate inhibition may be 
tricky because of poor correlation existing between the activity of the beta 
lactamase and different types of inhibitor substrates and also the organisms 
may imbibe additional resistance mechanisms which may hide the existence of 
ESBL activity was explained by Avinash et al
100
. The other coexistence factors 
include the presence of AmpC- enzymes, changes in porin structure. This 
makes TEM and SHV type beta lactamases to mutate at their coding sequences 
which makes them resistant to the inhibitory action of clavulanic acid. 
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 Klebsiella pneumoniae posses plasmid mediated AmpC and they are not 
chromosomal mediated. In the study AMPC production by Klebsiella 
pneumoniae was14(21.21%) by screening test and by Confirmatorytest it was 
11 (16.6%) in burns wound and total AMPC production along with 
coexsistence of ESBL was 21.21%.This is similar to the study done by, varsha 
gupta et al
43
 showed 20%, Vinod kumar et al
 101 
it was (22.22%) and gunawati 
et al 
102
 19.6%. Higher percentage was seen in mundhada et al
70
 65.1% and 
Narinder kaur et al
62
 26.7% AMPC producing Klebsiella pneumoniae was 
isolated 
 
 In surgical site infection by screening test 6(22.92%) and 5(18.51%) 
were confirmed for AMPC productin in Klebsiella pneumoniae and total 
AMPC production was 25.92%in surgical site infection which is contrary to the 
study by narayan Prasad et al 
103 
it was32.1%. 
 
  In the study 14.28% diabetic ulcer showed Ampc production which is 
similar to the study by chittur yerat
104
 et al 14% AMPC was produced in 
Klebsiella pneumoniae. 
 
 Those isolates which were cefoxitin resistant by screening test and 
AmpC negative by confirmatory test may be due to changes in the permeability 
and mutations of porin channels.
    
 
 Detection of Co-Existence of ESBL & AmpC Production in AMPC 
productin in Klebsiella pneumoniae by Ampc disk diffusion test showed 
3(4.5%) from burns and 2(7.4%) from surgery. Totally 5(4.42%) cases were 
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detected for both Esbl and Ampc production. This correlated with the studies 
done by varsha gupta et al
43
 were they showed 5% of co expression and.kaur et 
al
84
. Ampc & Esbl 7.1% while in loveena oberoi
89
 it was 22.2% this may be 
due to propagation of plasmid mediated AMPC among the enterobactericea 
possesing Esbl enzyme.  
 
 AmpC generating organisms may act as a hidding pool for the ESBLs. 
High level expression of AmpC can also prevent the identification of the ESBL
.
 
Cefepime present in the 4
th
 generation cephalosporins had the ability to detect 
ESBL, as increasing amount of AmpC production had least effect on the 
activity of cefepime.Thus this drug is more dependable in identifying ESBL co-
existing AmpC
100
. 
 
 On the whole total ESBL isolates among Klebsiella pneumoniae in 
wound infection in the study was 46.01%. It correlates with study done by shiju 
MP etal
105
 were 48.53%, metribasavaraj 
106 
46.4%, No yilmazet al
107 
46% and 
in sukumar nirmala et al
108
 it was 49% ESBL. Contrary to this study higher 
percentage was seen in 62.2% sridar et al
109
 showed 67.04%, 67% by meeta 
Sharma et al
110
, 50% in gaurav dalela et al
85
 , and52.27% manider kaur et al
111
 
and 55.5% in padmaja et 
a112l
.While lower percentage (33.3% )was seen in 
yahaya Mohamed et al
113
, 30.19% in shukla et al study
114
., 14% in MS kumar 
et al
115
, 15.8% by ravichitra et al
116
 and loveena oberoi
89
 showed 15.62% ESBL 
in Klebsiella pneumoniae 
 
 Most of the studies including this study shows higher percentage of 
ESBL production indicating high prevalence of ESBL among Klebsiella 
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species. This is because of extensive use of extended spectrum antibiotics that 
had lead t multidrug resistant as they are plasmid mediated 
 
 Total Ampc production in Klebsiella pneumoniae in the study was 
20.35%. Contrary to our study Higher percentage was seen in jaspal kauret al
84 
(46.1%) varsha gupta kathikeyan et al
44
 32% and tanushree barura et al
117
it was 
34.3%. Sheevani Seemar et al
118
 25%., parveen R. mohamudha
119
&shanthi et 
al
120
 it was 3%. But Anand manoharan et al
121
 showed 12.5%. In Loveena 
oberoi et al 
89 
(6.67%), no yilmaz
107
 3.6%, Leila azmi
122 
(1.6%) and Khan 
mohammed Nasir et al
123 
(9.8%) showed lower percentage of Ampc production 
in Klebsiella pneumoniae 
 
 In the study Carbpenemase producing Klebsiella pneumoniae detected 
by screening method was 9(13.63%) and by modified carbapenem inactivation 
method in burns was 8(12.1%). In surgical site infection by screening method 
was 4(14.81%) & MCIM was 1(3.70%). Total carbapenem production in 
wound infection in this study by screening test was 12.38% and by 
confirmatory test it was 7. 96%.This study was similar to the study done by 
Smita sood
124 
it was 8.33% and in manisha sahu et all
125
 it was 11% and But 
most of the study showed higher percentage. Inpriya darshini shanmugam et 
al
96
 it was 34.7%, Humaira basher et al 
126 
22.8%,. Mohanthy et al it
127
 was 
24.03%. CDC identified from January 2011- jan 2014 30% CRE, Nagaraj et 
al
128
 CRE 18%. gaind et al
24
 CRE 24.03% and Anand manoharan et al
121
 
12.5%, arjith arora
129 
15.57% and very lower percentage, 4.8% Carbpenemase 
producing Klebsiella pneumoniae was identified by vinod kumar et al
101
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 Wide spread of multidrug resistant ESBLs has imposed selective 
pressure on carbapenems and along with added porin loss in AMPC producer 
had resulted in carbapenem resistant. The resistance by serine carbapenemase 
posses bla KPC, bla VIM& bla IMP while zinc carbapenemase or metallo β- 
lactamase are encoded by bla NDM. The lower percentage of carbapenemase 
production in this study shows the need of effective surveillance.  
 
 In the study all 9 carbapenemase producing Klebsiella pneumoniae 
isolates showed bla NDM gene positive and KPC &IMP were negative by 
molecular method. Prevalence of 34.8% KPC was seen in lascols et al 
130
. 
while N agaraj et al
128
 & mohan et al
131
 did not find any KPC. p.mathur et al
132
 
noted. In deshpande et al
133
 & manoj kumar et al
134
 it ndm was 33.3% and 
Sharma 
61
 et al ndm 33%, arjith bora et al 
129 
isolated 13.04%of NDM gene. In 
Balvinder mohan et al
135A,B
 detected 9.5% NDM. CDC report from January 
2011- jan 2014 shows CRE isolates were 30%in which KPC gene 93% and 
NDM 7%. In mohanthy et al 
127
 NDM detected was 65.6% & KPC was 2.1%. 
Nithya et al 
136
 NDM detected in Klebsiella pneumoniae was 14%. 
 
 In this study out of 9 carbapenemase producing Klebsiella pneumoniae, 
one was only MBL producer, 4 strains showed co exsistence of ESBL and 
another 4 showed co expression of AMPC production. All 4 ESBL strain 
carried the bla SHV,bla TEM and blaCTX gene identified by PCR technique. 
In nithya et al
136 
coproduction of ESBL & MBL were 7%. Loveena oberol et 
al
89 
16.67% carried both ESBL & MBL strains.Sheevani Sharmaet al
118
 and 
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khan mohammedetal
123
 showed both MBL & ESBL coexpression to be 11.2%. 
 In.ajith arora
129
 all the three ESBL gene and bla NDM gene coexsisted. 
Devi et al
137
 showed the presence of all the three gene to co exsist in ESBL 
strain.begum fouzia
87
 showed TEM and SHV gene co expression.Meeta 
Sharma etal 
110 
showed 9 out of 20 esbl to carry the three genes. Loveena 
oberoi et al
89
 study 10 % klebsiella species showed both AMPC & MBL 
coexpression. parween mohammed 
119 
showed plasmid mediated Ampc to be 
29.3%. yilmaz
109
 showed the presence of plasmid mediated AMPCin Klebsiella 
pneumoniae in their study. 
 
 In this study Esbl producing Klebsiella pneumoniae showed maximum 
sensitivity to meropenem (96%), tozabactum, piperacillin (92.3%) and 
amikacin (73.07%), cefepime 73.07% and lower sensitivity to ciprofloxacin 
(18%) and cotrimoxazole(2%) 
 
 This is similar to the study done by Ami variaya et al 
78
 showed 100% 
sensitivity to meropenem,piperacillin/tozabctum 84.3%, amikacin 63.5% and 
co-trimoxazole 26.8%. 
 
 kavita et al
95
 showed sensitivity to amikacin & piperacillin/ tozabactum 
was 86.66%, and sensitivity to ciprofloxacin & cotrimoxazole 20%. Meeta 
Sharma et al
110
 the sensitivity to meropenem 100%, amikacin 54.17% 
piperacillin/tozabactum 46.67%, gentamicin 39.17%  & ciprofloxacin 18.18%. 
Gauav dalela et al
85
, meropenem I 98.5%, piperacillin/tozabactum 72.6%, 
amikacin 64.5%, ciprofloxacin, 36.3% & cotrimoxazole 13.3%.  
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 In the study maximum resistant was shown to gentamicin, 
cotrimoxazole, and ciprofloxacin by ESBL producing Klebsiella pneumoniae. 
As ESBL encoded gene are present on large conjugated plasmid they are easily 
transferrable to other enterobactericeae thereby spreading antibiotic resistant in 
the community
7 
 
  In the study AMPC producing Klebsiella pneumoniae were highly 
sensitivity to 91.30% meropenem,65.21% amikacin, & 60.86% cefepime, 
lower sensitivity was seen with 3
rd
 generation cephalosporins, to ciprofloxacin 
it was 17.39% & Cotrimoxazole 4.3 %.  High level of expression shown by 
plasmid mediated AMPC enzyme resulted in significant level of resistant to 
beta lactam antibiotics
117
. In studies by Varsha gupta karthikeyan et al
44
 it was 
100% sensitivity to meropenem, amikacin 70% & piperacillin/ tozabactum 
63%., ciprofloxacin 37%, cefepime 32%. In Vandhana et al 
138 
meropenem 
1OO%, piperacillin/tozabactum 52%, AK 33%, cefepime 8%, cot 10%, 
gentamicin18%. anand manoharan et 
al121 
meropenem 100%, ak 85%, piptaz 
74.6%. 
 
 The sensitivity pattern of Carbapenemase producing Klebsiella 
pneumoniae in the study showed 66.6% sensitivity to amikacin, 44.4% 
togentamicin and 33.3% piperacillin/tozabactum while lower sensitivity was 
seen with cotrimoxazole 0% and ciprofloxacin 22.2% 
 
 The resistant pattern of carbapenamase in other studies were, Mohanthy 
et al
127
 resistant to, amikacin 74%, gentamicin 91. 4%, ciprofloxacin 90.3%, 
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piperacillin/tozabactum 94.6%. Priyadarshini et al
96 
100% resistant to 
cotrimoxazole & piperacillin/tozabactum, cefepime 96%, ciprofloxacin 91%, 
amikacin 59%, and gentamicin 73%. Humaira bashiret al
126
 97.7% resistant to 
piperacillin/ tozabactum, cefepime 95.8% and ciprofloxacin 28.4% similar to 
our study Elizabeth et
139
 al showed maximum sensitivity to gentamicin was 
58.3% & Amikacin 53.3%, and Smita sood
124
 amikacin was 18.33%. all the 
MBLS were susceptable to colistin 
 
 Out of 113 cases 13 patients expired due to burns wound infection along 
with added factors like increased raw body surface area that are fertile for the 
growth of bacteria,loss in body fluid and impending shock. Out of 13 patients 
expired 5 had carried only ESBL and 4 had both MBL & ESBL, 3 had MBL & 
AMPC and 1 case of ampc & esbl and. The mortality rate in the study by 
shankar srinivasa et al
71
 was 10% due to burns. p.mathur et al
132
 noted Fatal 
outcome of bla ndm was 47%. shanmuganathan
140
 showed 25% mortality was 
associated with ESBL. 
 
 In Diabetic foot ulcer 3 cases were amputated all the 3 carried Esbl 
strains and showed poly microbial growth with poor glycemic control and 
longer duration of diabeties and poor follow up. These patients showed poly 
microbial growth 
 
 In surgery 2 cases went in for sepsis and recovered. These patients 
showed not only poly microbial growth but also carried the ESBL resistant 
strain.  
 81 
 
 The co-existence of various beta lactamases enzyme in a particular 
bacterial isolate often complicates the diagnostic and treatment modalities, 
posing a challenge and limiting the treatment options to fourth generation 
cephalosporins or carbapenems which ultimately leads to the development of 
carbapenem resistance also. 
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SUMMARY 
 
 800 wound samples was collected from patients with wound infection, 
from various department for a period of one year from june 2017 to May 
2018. Specimen were, cultured and bacterial pathogens were identified 
by Standard microbiological techniques  
 Out of 394 culture positive growth, 74.16% had monomicrobial growth 
and 25.63% had polymicrobial growth. Out of this 66.5% was Gram 
negative bacteria and 33.44% was Gram positive bacteria 
  Staphylococcus aureus (26.27%) was the predominant Gram positive 
bacteria isolated. Among Gram negative bacteria Klebsiella species 
(21.16%) was the predominant organism isolated followed by 
Pseudomonas aeruginosa (20.81%) 
 Out of 113 Klebsiella species isolated, 103(26.14%) was Klebsiella 
pneumoniae and 10 (2.53%) were Klebsiella oxytoca.Maximum number 
of Klebsiella species was isolated from burns wound infection (41.67%), 
followed by diabetic foot ulcer (24.56%) and surgical site infection 
(21.25%) 
 Anibiotic Sensitivity pattern by Kirby bauer disk diffusion method 
showed maximum sensitivity to Meropenem, Pipperacillin tozabactum, 
Amikacin, Gentamicin and least sensitivity to Cotrimoxazole and 
Ciprofloxacin. 
 Total ESBL producers among Klebsiella pneumonia isolates was 
51.51% in burns wound infection, 44.44% in surgical site infection and 
42.85 % in diabetic foot ulcer. 
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 AMPC producer among Klebsiella pneumoniae isolates was 21.21% in 
burns wound infection , 25.92% in surgical site infection and 14.28% in 
diabetic foot ulcer. 
 Co exsistence of ESBL & AMPCproducer in Klebsiella pneumoniae 
isolates was 4.5% in burns wound and 7.4% in surgical site infection. 
 MBLproducers among Klebsiella pneumoniae was 12.1% from burns 
wound infection and 3.7% from surgical site infection. 
 Resistant pattern seen in wound infection produced by 103 Klebsiella 
pneumoniae isolates includes 52 (46.01%)  ESBL producer, 23(20.35%) 
AMPC producers and 9(7.96%)  carbapenemase producers. 
 Among the 9 carbapenemase producing Klebsiella pneumoniae isolates, 
all the 9 carried the bla NDM gene identified by PCR. 4 out of 9 strains 
showed coexistence of ESBL & MBL and another 4 showed MBL & 
AMPC co-existence. All the 4 ESBL strains possesed blaSHV, blaTEM 
& blaCTX gene and all 4 Ampc producers carried the Ampc gene. 
  ESBL & AMPC producing Klebsiella pneumoniae showed maximum 
sensitivity to Meropenem 96% & 91.3% respectively and least 
sensitivity to cotrimoxazole 2% & 4.3 respectively. Carpapenamase 
producing Klebsiella pneumoniae showed maximum sensitivity to 
Amikacin 66.6% and least sensitivity to cotrimoxazole and 
ciproflxoacin. All the MBL producing strains were susceptible to colistin 
 
 13 Patient who carried the resistant strain expired in burns infection 
along with other underlying causes. 3 cases with diabetic foot ulcers was 
amputated as they carried resistant strains. 
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CONCLUSION 
 
 In the study Klebsiella species was the most common Gram negative 
organism isolated from wound infection. ESBL, AMPC and MBL lactamases 
was detected among the Klebsiella species isolated. They showed high degree 
of resistance to antibiotics. This not only delayed the process of wound healing 
but also ended up in fatal outcomes.So it is important to control the emergence 
of antibiotic resistant globally. This could be achieved by performing screening 
and confirmatory test routinely in microbiological laboratories, and also by 
following simple measures like hand washing and strict adherence to hospital 
antibiotic policy, the occurrence and spread of resistant strains can be 
prevented in wound infection. This will enable in better wound healing, there 
by preventing mortality and morbidity. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 PROFORMA 
Name                                                 Lab. No  
Age/Sex                                               IP / OP No: 
Ward & Date of Admission: 
H/O of Presenting illnness 
Duration:                                    
Cause: 
Type  of  infection: 
Past History: (DM/HT/TB/CHD/Surgery) 
LAB INVESTIGATION: 
 
Microscopic Finding 
          Direct Gram Stain 
 
Culture Characteristics 
          Blood Agar 
          Mac Conkey Agar  
         Nutrient Agar 
Biochemical Reactions 
 
Antibiotic Susceptibility Pattern 
ESBL  :         Amp C    :   Carbapenemase (MBL&KPC): 
 
Genotype 
     
Signature of Investigator  Signature of the Guide 
 PATIENT CONSENT  FORM 
 
STUDY OF PHENOTYPIC AND GENOTYPIC CHARACTERISATION 
OF ANTIBIOTIC RESISTANT KLEBSIELLA SPECIES ISOLATED 
FROM WOUND  INFECTION WITH SPECIAL REFERENCE TO 
CARBAPENEM RESISTANCE 
 
STUDY CENTER: KILPAUK MEDICAL COLLEGE AND HOSPITAL, 
CHENNAI. 
 
PATIENT NAME:    PATIENT AGE: 
 
IDENTIFICATION NUMBER: 
PATIENT TO TICK (        ) THESE BOXES  
 
 I confirm that I have understood the purpose of procedure for the above 
study.  
 
 I have the opportunity to ask the question and all my questions and 
doubts have been answered to my satisfaction. 
 
 I understand that my participation in the study is voluntary and that I am 
free to withdraw at anytime without giving any reasons, without my legal rights 
being affected. 
 
 I understand that investigator, regulatory authorities and the ethics 
committee will not need my permission to look at my health records both in 
 respect to the current study and any further research that may be conducted in 
relation to it, even if withdraw from the study, I understand that my identity 
will not be revealed in any information released to third parties or published, 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
 
 I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperative with the study 
team and to immediately inform the study staff if I suffer from any 
deterioration in my health or wellbeing or any unexpected or unusual 
symptoms. 
 
 I hereby give consent to participate in this study. 
 
 I hereby give permission to undergo complete clinical examination and 
diagnostic test. 
 
 
Signature/Thumb impression:  Place:  Date: 
Patient name and address: 
Signature of the investigator:  Place:  Date: 
Study investigator’s name: 
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மநற்சகாள்ல௃ம் ம஧ாதும் இந்த ஆய்வில் ஧ங்குச஧றும் நருத்துவர் 
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 APPENDIX 
 
PEPTONE WATER
35 
Peptone - 10g 
Sodium chloride - 5g 
Distilled water - 1 litre  
Dissolve the ingredients in warm water, adjust the pH to 7.4 -7.5 and filter. 
Distribute as required and autoclave at 121 degree Celsius for 15 mins.  
 
BLOOD AGAR 
35 
Sterile sheep blood - 50 ml  
Peptone - 10 g 
Beef extract - 3g 
Sodium chloride - 5 g  
Distilled water - 1000 ml  
Autoclave the nutrient agar base at 121º C for 15 minutes and blood with sterile 
precautions and distribute in Petri dishes.  
 
MAC CONKEY AGAR
35
  
Peptic digest of animal tissue - 17g  
Proteose peptone - 3g 
Lactose - 10g 
Bile salts - 1.5g 
Sodium chloride - 5g  
Neutral red - 0.03g 
 Agar - 15g 
Distilled water - 1000 ml 
Final pH at (25º C) 7.1±0.2.  
Suspend 51.53 grams in 1000 ml of distilled water. Heat to boiling to dissolve 
the medium completely. Sterilize by autoclaving at 15 lbs pressure (121ºC) for 
15 minutes. Mix well and pour into Petri dish plates. 
 
NUTRIENT AGAR
35 
Peptic digest of animal tissue - 5g 
Beef extract - 1.5g  
Yeast extract - 5g  
Agar - 15g 
Distilled water - 1000ml  
Dissolve the contents in water and mix by heating. Autoclave at 121° C for 15 
minutes. Adjust pH to 7.4 + 0.2. Pour 20-25 ml of 9 cm diameter. Petri dishes 
to give 4 mm thickness 
 
1. OXIDASE TEST 
35,7 
 This test is mainly done to differentiate organisms lacking cytochrome 
oxidase enzyme, mainly the members of enterobactericeae. This enzyme helps 
in the transfer of electrons to oxygen, with formation of water. The dye 
tetramethyl paraphenylene diamine dihydrochloride is substituted for oxygen as 
artificial electron acceptor. In the reduced state, it is colorless and in the 
presence of cytochrome oxidase and oxygen it forms indophenol, which is 
 purple. Strips impregnated with dried reagents were used. The colony was 
taken on a wooden stick and smeared onto the strip. The appearance of purple 
color within 10 sec. was taken as positive. 
 
 2. CATALASE TEST 
35,7 
 Organisms’ possessing the enzyme catalase splits hydrogen peroxide 
into water and oxygen. The evolution of oxygen appears as bubbles. Tube 
catalse test was performed 3ml of 3% Hydrogen peroxide was taken in a test 
tube. The colony of the organism to be tested was taken on a glass rod and 
introduced into the tube. Appearance of brisk effervescence was taken as 
positive. 
 
3. MOTILITY
35,7 
 Motility was done by hanging drop method. A drop of saline with the 
test organism was placed on the coverslip. The hanging drop slide is inverted 
over the coverslip where wax had been applied on the corners. The slide is 
turned quickly so that drop is in centre of the concavity. The edge of the drop is 
focused on the low power and high power objectives. Motility was observed. 
 
4. INDOLE TEST
35,7 
 Indole is a benzyl pyroll which is a metabolic product of tryptophan. 
Bacteria which possess tryptophanase hydrolyse trytophan to indole. The 
organism was inoculated in peptone water medium, incubated at 370C for 18-
24 hours, 1ml of zylene was added and Erlichs’reagent (Para dimethyl amino 
 benzaldehyde) was added drop by drop. Formation of fuchsia red ring was 
positive. It is a red complex of indole and paradimethylaminobenzaldehyde. 
 
5. TRIPLE SUGAR IRON MEDIUM 
35,7 
 Triple sugar iron medium was taken and the organism was stabbed to 
the butt as well streaked on the surface. It was incubated for 18-24hours at 
370C, and then looked for the presence of growth and change in pH Growth 
with no change in PH (slant and butt) indicated the organism to be 
nonfermenting. 
 
6. CITRATE UTILIZATION TEST 
35,7 
 Sodium citrate is a salt of citric acid seen in metabolism in Krebs cycle. 
Some bacteria utilize citrate as the sole source of carbon and it is detected by 
the production of alkaline by products Christensen’s citrate media was used. 
The organisms were streaked on the surface of the slant and incubated at 370C 
for 18-24hrs. Development of deep blue color of the medium with growth was 
taken as positive. 
 
8. UREASE TEST 
35,7 
  Urea is a diamide carbonic acid which when hydrolyzed releases 
ammonia and carbon dioxide. Urease is an enzyme when present hydrolyses 
urea and release ammonia changing the medium to alkaline, PH. The organism 
was streaked on the surface of the slant and incubated at 370C for 18-24 hours. 
Development of magenta pink of the medium along with growth was taken as 
positive. 
  9. NITRATE REDUCTION TEST 
35,7
  
 The capacity of an organism to reduce nitrates to nitrites is shown by 
this test. The presence of nitrate in the medium is detected by addition of a 
naphthalamine and sulphanilic acid. The organism was inoculated in nitrate 
broth and incubated at 370C for 18-24 hours and observed for gas production 
by Durham’s tube. One ml each of reagents a naphthalamine & sulphanilic acid 
were added simultaneously and looked for the development of red color. 
Development of red color was taken as positive and when it was negative zinc 
dust was added. When the red color developed after adding zinc the test was 
taken as negative because it indicated the presence of residual nitrates. 
 
SPECIAL BIOCHEMICAL TESTS USED FOR IDENTIFICATION OF 
NON FERMENTERS  
1. HUGH – LEIFSON OXIDATION - FERMENTATION 
MEDIUM
35,7
  
2. Peptone: 2g  
3. Sodium Chloride: 5g 
4.  D-Glucose: 10g 
5.  Bromothymol blue: 0.03g 
6.  Agar: 3.0g  
7. Dipotassium Phosphate: 0.3g  
8. Distilled water: 1 litre  
9. pH: 7%  
 
  Medium was sterilized by autoclaving. After cooling the medium to 
450C, filter sterilized carbohydrate solution was added to get a final 
concentration of 1% Carbohydrates used for the study were glucose, maltose, 
xylose, fructose and mannitol. Of medium was poured as a butt and without a 
slant into tubes. Two tubes were required for the test, each inoculated with the 
unknown organism, using a straight needle stabbing the medium three to four 
times half way to the bottom of the tube. One tube of each pair was covered 
with a 1cm layer of sterile mineral oil (or) melted paraffin, leaving the other 
open to the air. Both tubes were incubated at 350C and examined daily for 
several days. 
  
 In case of oxidative metabolism, yellow color appears along the upper 
one fourth of the medium and in the tube where no oil overlay was done. In 
case of fermentative organisms yellow color develops in both the tubes 
 
CONTROL  
Glucose fermentation: Escherichia coli 
Glucose oxidation: Pseudomonas aeruginosa  
Non saccharolytic: Alcaligenes species. 
 
1. DECARBOXYLATION OF LYSINE, ARGININE & ORNITHINE 35,7 
 Decarboxylases are a group of specific enzymes which react with carboxyl 
portion of aminoacid forming alkaline reacting amines. The reaction is 
decarboxylation. Each enzyme is specific for Lysine, Arginine and 
Ornithine. 
 INGREDIENTS  
1. Yeast extract: 5g  
2. Peptone: 5g  
3. Glucose: 0.5g  
4. Pyridoxal: 5mg 
5.  Bromocresol Purple: 5ml 
6.  Cresol Red: 2.5ml 
7.  Distilled water: 1 ltr.  
All aminoacids were added individually to a final concentration of 1% pH 
adjusted at 6.0 & autoclaved at 15lbs for 15 minutes. 
 
PROCEDURE  
 The organism was inoculated in four tubes. One having the basal 
medium without aminoacid for control. Other three tubes having lysine, 
arginine and ornithine each. All tubes were overlaid with liquid paraffin. All 
were incubated at 370C for 24 hours. The control tube turned yellow indicating 
that the organism is viable and the test medium turning blue purple indicating 
positive result.  
 
3. O–NITROPHENYL β - D GALACTOPYRANOSIDE 35,7  
Reagent 
Sodium Phosphate buffer 1M  pH 7.0 – 5ml  
O – Nitrophenyl β - D – galactopyranoside – 80mg  
Distilled water – 15ml.  
 A dense suspension of the test organism grown in TSI agar was prepared in 
saline. About 1 drop of toluene was added to the suspension and 0.2ml of 
ONPG solution was added to the suspension and incubated at 370C β -
galactosidase producing organism show yellow color after 1 hour or 18-24 
hours incubation. 
 
CONTROL 
 Positive Control – Escherichia coli  
Negative control – Proteus species. 
 
5. GELATIN LIQUEFACTION TEST 
35,7
  
 Gelatin breakdown can be demonstrated by incorporating it in a buffered 
nutrient agar, growing the culture and then flooding the medium with mercuric 
chloride that differentially precipitates either gelatin or its breakdown products 
causing opacity in the medium with clear zones around gelatin-liquefying 
colonies  
 
CONTROL Positive control: Pseudomonas aeruginosa 
 Negative Control: Stenotrophomonas maltophilia  
 
PCR Primers 
SHV-     Forward -GCCCGGGTTA TTCTTATTTGTCGC  
                Reverse: TCTTTCCGATGCCGCCGCCAGTC 
 TEM  : Forward  -GGGGAGCTCATAAAA TTCTTGAAGAC  
              Reverse   -GGGGGATCCTTACCAATGCTTAATC A 
 CTX :  Forward-CGCTGTTGTTAGGAAAGTGTG 
  Reverse-GGCTGGGTGAAGTAAGTGAC 
Ampc:  Forward primer: ATTCCGGGTATGGCCGT 
             Reverse primer: GGTTTACCTCAACGGC 
blaNDM ;  Forward primer: GGTTTGGCGATCTGGTTTC 
                Reverse primer: CGGAATGGCTCATCACGATC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ABBREVIATIONS 
 
MDR   -  Multidrug resistant  
PDR  -  Pandrug resistant  
ESBL  - Extended Spectrum Betalactamases  
MBL   -  Metallo betalactamases  
KPC  - Klebsiella pneumoniae carbapenemase 
ATCC  -  American Type Culture Collection  
CLSI  -  Central Laboratory Standards Institute  
CDC  - Centre for disease control 
TBSA  - Total body surface area 
SSI  -  Surgical site infection  
E- TEST  -  Epsilometer Test  
FDA   -  Food and Drug Administration (United States USFDA)  
OPD   -  Out Patient Department 
MALDI–TOF - Matrix Assisted Laser Desorption/Ionisation – Time of Flight.  
DDST  -  Double Disc Synergy Test  
CDDT  -  Combined Disc Diffusion Test  
DPT   -  Disc Potentiation Test  
MHA  -  Mueller Hinton Agar  
MIC   -  Minimum Inhibition Concentration  
PCR   -  Polymerase Chain Reaction  
PFGE  -  Pulsed-Field Gel Electrophoresis  
SPSS   -  Statistical Package for Social Science 
 KEY TO MASTER CHART 
 
M   -  Male patient  
F   -  Female patient  
IP   -  Inpatient  
OP   -  Outpatient  
DM   -  Diabetes Mellitus  
P   -  Positive  
N  -  Negative  
S   -  Susceptible  
R   -  Resistant  
CTX  - Cefotaxime 
CTR   -  Ceftriaxone  
CAZ   -  Ceftazidime  
AK   -  Amikacin  
GEN   -  Gentamicin  
CIP   -  Ciproflaxacin  
COT   -  Cotrimoxazole  
PIT  - Piperacillin tazobactam  
CX   -  Cefoxitin  
CL  - Colistin 
MRP   -  Meropenem 
ESBL  -  Extended spectrum betalactamases  
MBL  -  Metallobetalactamases  
Amp C  -  AmpC betalactamase 
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MASTER CHART 
 
Column1 AGE SEX DEGREE % GM STAIN ORGANISM AK GEN CIP COT CTX CAZ AMC CX CPM MRP PIP/TOZ OUTCOME 
2440 36 f 1&2nd⁰ 22% pu+,GNB+ PS/KP S S R R R R S S S S S RECOVERED 
2416 41 F 1&2nd⁰ 12% pu+,GNB+ acineto             
2415 38 F 1&2nd⁰ 18% pu+,GNB+ kp S S R R R S S R S S S RECOVERED 
2414 42 M 1st 10% pus_org- ng             
2413 17 M 1&2nd⁰ 18% pu+,GNB+ kp/ps S S R R R R R R S S S RECOVERED 
2412 50 M 1&2nd⁰ 23% pus+gnb&gpc+ ps/sa             
2411 3 MCH 1&2nd⁰ 10% pus_org- ng             
2410 24 M 2nd&3rd 75% pu+,GNB+ kp S R R RR R R R R R R S EXPIRED 
2409 22 F 1&2nd⁰ 9% pus_org- ng             
2408 32 F 1&2nd⁰ 18% pu+,GNB+ ps             
2406 50 F 1&2nd⁰ 23% pus+gpc+ sa             
2405 21 M 1&2nd⁰ 16% pu+,GNB+ ps             
2404 36 F 1&2nd⁰ 26% pu+,GNB+ ps/kp S S S R R R S S S S S RECOVERED 
2403 1 1/2 MCH 1st 15% pu+,GNB+ ps             
2402 47 F 1&2nd⁰ 12% pus_org- ng             
2401 40 F 1&2nd⁰ 17% pus+gpc+ sa             
2400 24 M 1st 9% pus_org- ng             
2399 12 M 1st&2nd 22% pu+,GNB+ ps/kp S R R R R R S S S S S RECOVERED 
2398 22 F 1&2nd⁰ 14% pus_org- ng             
2389 38 F 2nd&3rd 55% pu+,GNB+ KP/ACIN R S R R R R R R R R S EXPIRED 
2387 80 F 1&2nd⁰ 10% pus_org- ng             
2386 26 F 2nd&3rd 10% pus_org- ng             
2385 38 F 1&2nd⁰ 21% pu+,GNB+ kp S R S R S S S R S S S RECOVERED 
2384 35 MCH 1st scab pus_org- ng             
2383 11 F 1&2nd⁰ 14% pus_org- ng             
2382 45 F 1st&2nd 22% pu+,GNB+ ps             
2381 40 F 1&2nd⁰ 13% pus_org- ng             
2380 22 F 1&2nd⁰ 33% pu+,GNB+ acineto             
2379 25 FCH 1&2nd⁰ 11% pus_org- ng             
2368 11 M 1&2nd⁰ 33% pu+,GNB+ kp/ps S S S R S S S S S S S RECOVERED 
2367 60 F 1&2nd⁰ 15% pus+gpc+ sa             
2366 34 F 1st 10% pus_org- ng             
2365 25 F 2nd&3rd 34% pu+,GNB+ kp/ps S R R R R R R S S R S RECOVERED 
2364 38 M 1&2nd⁰ 28% pus_org- ng             
2363 40 M 1&2nd⁰ 15% pus_org- ng             
2362 31 M 1&2nd⁰ 15% pus_org- ng             
2361 48 F 1&2nd⁰ 22% pu+,GNB+ ps             
2360 11 M 2nd&3rd 35% pu+,GNB+ kp/ps S S S R S S S S S S S RECOVERED 
2359 50 F 1&2nd⁰ 18% pu+,GNB+ kp/ps S S R R S S S R S S S RECOVERED 
2358 17 M 1st 11% pus_org- ng             
2357 28 F 1st 9% pus_org- ng             
2341 24 M 1&2nd⁰ 25% PUS-ORG- NG             
2340 19 F 1&2nd⁰ 9% pus_org- ng             
2339 45 F 1&2nd⁰ 10% pus_org- ng             
2338 51 F 1&2nd⁰ 43% pu+,GNB+ acin             
2337 17 M 1&2nd⁰ 26% pu+,GNB+ kp S S R R R R R S S S S RECOVERED 
2336 45 M 1&2nd⁰ 12% pus_org- ng             
2330 38 F 1&2nd⁰ 43% pu+,GNB+ ent/ps             
2329 17 M 1&2nd⁰ 23% pu+,GNB+ ps             
2328 50 F 1&2nd⁰ 11% pus_org- ng             
2327 24 F 1&2nd⁰ 21% pus_org- ng             
2326 66 fch 1st scab pus_org- ng             
2325 12 f 1&2nd⁰ 23% pu+,GNB+ kp S S R R R R R S S S S RECOVERED 
2324 38 M 2nd&3rd 31% pu+,GNB+ kp/ps S S R R R R R R R R R RECOVERED 
2322 60 M 1st 11% pus_org- ng             
2321 2 FCH 1&2nd⁰ 34% pu+,GNB+ ps             
2320 3 F 2nd&3rd 35% pu+,GNB+ kp R S R R R R R R R R S EXPIRED 
2319 25 F 1&2nd⁰ 17% pus_org- ng             
2318 30 M 1st 11% pus_org- ng             
2317 26 F 1st 9% pus_org- ng             
2307 26 F 2nd&3rd 33% pu+,GNB+ kp/ps S S R R R R R S S S S RECOVERED 
2306 52 F 1st 9% pus_org- ng             
2305 51 F 1&2nd⁰ 18% pus_org- ng             
2304 22 F 2nd&3rd 43% pus+gpc+ sa             
2303 21 F 1&2nd⁰ 12% pus_org- ng             
2302 10 M 1st 11% pus_org- ng             
2301 35 M 1st 9% pus_org- ng             
2300 45 F 1&2nd⁰ 27% pu+,GNB+ kp/ps R S R R R R R R R R S RECOVERED 
2292 19 F 1&2nd⁰ 14% pus_org- ng             
2298 56 F 1st 9% pus_org- ng             
2285 3 F 1&2nd⁰ 44% pu+,GNB+ pm             
2286 16 FCH 1st 9% pus+gpc+ cons             
2284 2 1/2 MCH 1st 10% pus_org- ng             
2283 5 1/2 FCH 1&2nd⁰ 19% PUS-ORG- NG             
2282 4 FCH 1st 11% pus_org- ng             
2281 3 MCH 1st 9% pus_org- ng             
2280 8 FCH 1st scab pus_org- ng             
2279 4 F 2nd&3rd 67% pus+gnb&gpc+ sa/ps             
2278 56 M 1&2nd⁰ 11% pus_org- ng             
2262 48 F 1&2nd⁰ 22% pu+,GNB+ ps             
2261 32 M 1&2nd⁰ 16% pus_org- ng             
2260 35 F 1&2nd⁰ 24% pu+,GNB+ pm/kp S R R R R R R R R R S RECOVERED 
2259 19 F 1st 10% pus_org- ng             
2258 10 F 2nd&3rd 54% pus+gnb&gpc+ acin/ent             
2246 16 F 1&2nd⁰ 12% pus_org- ng             
2245 31 M 1&2nd⁰ 13% pus_org- ng             
2244 60 M 1&2nd⁰ 9% pus_org- ng             
2243 50 F 1st 10% pus_org- ng             
2242 52 F 1st 11% pus_org- ng             
2222 24 FCH 1&2nd⁰ 12% pu+,GNB+ kp S S S R S S S R S S S RECOVERED 
2220 4 F 1&2nd⁰ 23% pu+,GNB+ ps             
2219 27 F 2nd&3rd 36% pus+gpc+ sa             
2218 24 M 1st 12% pus_org- ng             
2217 35 F 1&2nd⁰ 23% pu+,GNB+ kp S S S R S S S S S S S RECOVERED 
2216 32 F 2nd&3rd 88% pu+,GNB+ pm/kp S S R R R R R S S S S RECOVERED 
2215 34 F 2nd&3rd 43% PUS-ORG- NG             
2214 26 FCH 1st 10% pus_org- ng             
2213 10 F 1&2nd⁰ 18% pu+,GNB+ kp/ps S S R R R R R S S S S RECOVERED 
2206 15 M 1&2nd⁰ 10% pus_org- ng             
2201 39 M 1st 9% pus_org- ng             
2200 13 M 1&2nd⁰ 23% pus+gnb&gpc+ kp/sa S R R R R R R S S S S RECOVERED 
2199 49 FCH 2nd&3rd 34% PUS-ORG- NG             
2197 7 F 1&2nd⁰ 11% pus_org- ng             
2196 16 FCH 1st scab pus_org- ng             
2195 2 MCH 1st 9% pus_org- ng             
2194 5 1/2 M 1&2nd⁰ 22% pus+gnb&gpc+ kp/sa S R R R R R R S S S S RECOVERED 
2193 35 F 1&2nd⁰ 11% pus_org- ng             
2192 24 MCH 1&2nd⁰ 13% pus+gpc+ cons             
2191 8 M 2nd&3rd 53% pu+,GNB+ pm/ps             
2190 22 FCH 1&2nd⁰ 15% pu+,GNB+ kp/ps S S R R S S S S S S S RECOVERED 
2189 3 M 1&2nd⁰ 13% pus_org- ng             
2187 52 M 1st 11% pus_org- ng             
2186 49 M 1st 9% pus_org- ng             
2185 40 M 1&2nd⁰ 19% pu+,GNB+ kp/ps S S R R S S S S S S S RECOVERED 
2184 48 F 2nd&3rd 22% PUS-ORG- NG             
2183 35 F 1&2nd⁰ 28% pu+,GNB+ ps/cons             
2182 20 MCH 1st 9% pus_org- ng             
2181 6 F 1st 14% pus_org- ng             
2180 18 F 1&2nd⁰ 18% pu+,GNB+ kp/ps S R R R R R R S S S S RECOVERED 
2179 35 M 2nd&3rd 63% pu+,GNB+ ps             
2178 50 MCH 1st scab pus_org- ng             
2177 1 1/2 F 1&2nd⁰ 9% pus_org- ng             
2176 32 F 1&2nd⁰ 22% pus+ gpc+ cons             
2175 24 F 1&2nd⁰ 11% pus_org- ng             
2170 66 F 1&2nd⁰ 25% pu+,GNB+ ps/pm             
2168 16 F 2nd&3rd 76% pu+,GNB+ ps             
2165 26 M 2nd&3rd 78% pu+,GNB+ ps/kp S R R R R R R R R S S EXPIRED 
2164 31 F 1&2nd⁰ 32% pu+,GNB+ ps/kp S S R R R R R R R R R  
2150 53 M 1&2nd⁰ 13% pus_org- ng             
2149 40 F 1st 10% pus_org- ng             
2145 26 MCH 1st 9% pus_org- ng             
2144 2 M 1&2nd⁰ 22% pus+ gpc+ sa             
2143 8 FCH 1&2nd⁰ 13% pu+,GNB+ kp S S S R S S S S S S S RECOVERED 
2142 13 M 1&2nd⁰ 28% pu+,GNB+ kp/pm S S R R S S S R R S S RECOVERED 
2141 22 M 1st 12% pus_org- ng             
2135 50 F 1&2nd⁰ 11% pus_org- ng             
2134 33 M 1&2nd⁰ 11% pus_org- ng             
2133 42 F 1&2nd⁰ 10% pus_org- ng             
2132 31 F 2nd&3rd 65% pu+,GNB+ kp S S R R S R R S S S S EXPIRED 
2131 35 F 1&2nd⁰ 11% pus_org- ng             
2130 24 MCH 1st scab pus_org- ng             
2129 2 1/2 F 1&2nd⁰ 11% pus_org- ng             
2128 84 F 1&2nd⁰ 18% pu+,GNB+ kp S S R R S S S S S S S RECOVERED 
2114 30 M 2nd&3rd 32% pu+,GNB+ kp/ps S R R R S S S R S S S RECOVERED 
2113 39 M 2nd&3rd 65% pus+gnb&gpc+ ps/sa         S    
2111 63 F 1&2nd⁰ 22% pu+,GNB+ kp/ps S S S S R S R S S R S RECOVERED 
2109 34 F 1&2nd⁰ 46% pus+ gpc+ sa             
2108 19 F 1&2nd⁰ 32% pu+,GNB+ ps             
2107 78 M 2nd&3rd 65% pus+ gpc+ cons             
2078 22 F 1st 9% pus_org- ng             
2077 35 F 1&2nd⁰ 36% pus+ gpc+ sa             
2083 57 FCH 2nd&3rd 33% pus+gnb+ ps             
2082 6 F 1&2nd⁰ 23% pus+ gpc+ cons             
2081 56 M 1&2nd⁰ 23% pus+ gpc+ act/sa             
2080 42 F 1&2nd⁰ 55% pus+ gpc+ ent             
2063 17 M 2nd&3rd 37% pus+ gpc+ sa/ps             
2060 66 M 1&2nd⁰ 11% pus_org- ng             
2059 22 M 1&2nd⁰ 21% pu+,GNB+ kp/ps S S R R S R R S S R S RECOVERED 
2058 35 M 1&2nd⁰ 27% pu+,GNB+ pm/kp S S R R R R R S S S S EXPIRED 
2069 42 F 1&2nd⁰ 23% pus+ gpc+ sa             
2068 34 M 1st 10% pus_org- ng             
2067 39 M 1&2nd⁰ 18% pu+,GNB+ kp/ps S S R R R S R S S S S RECOVERED 
2066 35 M 1&2nd⁰ 22% pus+gnb+ kp S S R R S R R S S S S RECOVERED 
2065 30 M 1st 9% pus_org- ng             
2050 78 F 1&2nd⁰ 12% pus_org- ng             
2049 50 M 1&2nd⁰ 9% pus_org- ng             
2048 35 F 1&2nd⁰ 32% PUS-ORG- NG             
2047 58 F 1&2nd⁰ 27% pu+,GNB+ kp S S R R S S R S S S S RECOVERED 
2046 60 F 1&2nd⁰ 83% pus+ gpc+ sa             
2045 54 FCH 1&2nd⁰ 18% pus+ gpc+ sa             
2044 4 M 1st 14% pus_org- ng             
2039 47 M 1st 16% pus_org- ng             
2038 54 F 1&2nd⁰ 11% pus_org- ec             
2037 60 F 1&2nd⁰ 9% pus_org- ng             
2030 26 M 1&2nd⁰ 9% pu+,GNB+ kp/ps S R R R S S S R S S S RECOVERED 
2029 19 M 2nd&3rd 96% pu+,GNB+ kp S S R R R R R S S S S EXPIRED 
2028 32 M 1&2nd⁰ 43% pus+ gpc+ sa             
2015 45 M 2nd&3rd 42% pu+,GNB+ kp S R R R R R R R R R S EXPIRED 
2014 26 F 2nd&3rd 34% pus+ gpc+ sa             
2012 50 M 1&2nd⁰ 18% pus+ gpc+ sa             
2011 48 M 1&2nd⁰ 42% pus+ gpc+ sa             
1999 30 FCH 1st 9% pus_org- ng             
1991 8 M 1&2nd⁰ 14% pus_org- ng             
1990 62 F 1&2nd⁰ 44% PUS-ORG- NG             
1989 48 M 1&2nd⁰ 11% pus_org- ng             
1988 25 F 1&2nd⁰ 23% pu+,GNB+ kp S R R R S R S S S S S RECOVERED 
1987 1 MCH 2nd&3rd 55% pus+gnb&gpc+ kp/sa s R R R R S S S S R S expired 
1986 30 M 2nd&3rd 55% pus+gnb&gpc+ ps/sa             
1976 48 M 1&2nd⁰ 36% pu+,GNB+ ps             
1975 73 F 1st 11% pus_org- ng             
1971 18 M 1&2nd⁰ 13% pus_org- ng             
1970 19 M 1st 9% pus_org- ng             
1969 14 M 1&2nd⁰ 11% pus+ gpc+ ec/sa             
1968 18 F 2nd&3rd 33% pu+,GNB+ kp S S R R R S R S S S S RECOVERED 
1967 37 F 1&2nd⁰ 23% pu+,GNB+ kp/ps S S R R R S R S S S S RECOVERED 
1966 37 M 1&2nd⁰ 12% pus_org- ng             
1965 35 M 1&2nd⁰ 11% pus_org- ng             
1952 35 F 2nd&3rd 48% pu+,GNB+ kp R S R R R S R S S R S EXPIRED 
1951 32 M 1st 14% pus_org- ng             
1949 42 F 1st 11% pus_org- ng             
1939 50 F 2nd&3rd 48% pus+ gpc+ ec/sa             
1938 53 F 2nd&3rd 32% pu+,GNB+ ps             
1925 23 M 2nd&3rd 22% pus+gnb&gpc+ ps/sa             
1923 67 M 1st 11% pus_org- ng             
1922 30 F 1&2nd⁰ 33% pu+,GNB+ kp S S S R S S R S S S S RECOVERED 
1921 7 F 2nd&3rd 34% pu+,GNB+ kp/sa S R S R R R R R R S S EXPIRED 
1920 24 F 1&2nd⁰ 18% pu+,GNB+ ps             
1919 24 M 1st 11% pus_org- ng             
1918 47 M 1&2nd⁰ 21% pus+ gpc+ sa             
1917 13 M 1&2nd⁰ 13% pu+,GNB+ kp/pm S S R R S R R S R S S RECOVERED 
1916 65 F 1&2nd⁰ 30% pu+,GNB+ kp S S R R R S S S S S S RECOVERED 
1914 18 F 1&2nd⁰  pus_org- ng             
1913 30 F 1&2nd⁰ 12% pu+,GNB+ ps             
1911 2 MCH 1&2nd⁰ 13% pu+,GNB+ kp S R R R R S R S S S S RECOVERED 
1910 3 FCH 1&2nd⁰ 9% pus_org- ng             
1909 25 F 1&2nd⁰ 19% pu+,GNB+ ps             
1902 55 M 1&2nd⁰ 27% PUS-ORG- NG             
1901 48 M 1&2nd⁰ 12% pus_org- ng             
1900 34 M 2nd&3rd 18% pu+,GNB+ kp S S R R S S R S S S S RECOVERED 
1899 2 FCH 1st 9% pus_org- ng             
1898 1 MCH 1&2nd⁰ 16% PUS-ORG- NG             
1897 10 FCH 1&2nd⁰ 12% pus_org- ng             
1896 2 MCH 1st 11% pus_org- ng             
1895 14 MCH 1&2nd⁰ 15% pu+,GNB+ kp S S R R S S R S S S R RECOVERED 
1894 1 1/2 MCH 1st SCAB pus_org- ng             
1893 65 F 1st 13% pus_org- ng             
1892 24 F 1st 11% pus_org- ng             
1891 48 F 2nd&3rd 44% pu+,GNB+ kp/ps S S R R R R R S S S S EXPIRED 
1890 4 FCH 1st 11% pus+ gpc+ sa             
1889 2 1/2 FCH 1st SCAB pus_org- ng             
1888 40 F 1&2nd⁰ 14% pus_org- ng             
3053 17 f 1&2nd⁰ 15% pus_org- ng             
3052 27 f 1&2nd⁰ 23% pus_org- ng             
1887 21 F 2nd&3rd 69% pu+,GNB+ kp S S R R S S R S S S S EXPIRED 
2459 1 FCH 1ST SCAB pus_org- ng             
3037 40 f 1&2nd⁰ 15% pus_org- ng             
3057 20 m 1ST 13% pus_org- ng             
3056 17 f 1ST 11% pus_org- ng             
2460 45 F 1&2nd⁰ 32% pu+,GNB+ pm             
3055 25 m 1&2nd⁰ 24% pus_org- ng             
3054 33 m 1&2nd⁰ 22% pus_org- ng             
2461 48 F 2nd&3rd 22% pus+gnb+ ps             
2463 36 F 2nd&3rd 21% pu+,GNB+ kp/ps S S R R R S R S S S S RECOVERED 
2464 48 M 1&2nd⁰ 17% pus_org- ng             
2465 68 F 1st 9% pus_org- ng             
2466 60 F 1&2nd⁰ 9% pus_org- ng             
2468 22 F 1&2nd⁰ 38% pu+,GNB+ kp/ps S S S R R S R S S S S RECOVERED 
2469 22 M 1&2nd⁰ 11% pus_org- ng             
2470 11 MCH 1st SCAB pus_org- ng             
2482 33 F 1&2nd⁰ 21% pu+,GNB+ ps             
2490 30 M 2nd&3rd 33% pus+ gpc+ cons             
2492 25 F 2nd&3rd 43% pus+gnb&gpc+ kp/sa S S R R R S R S S S S RECOVERED 
2493 40 F 1&2nd⁰ 15% pus_org- ng             
2494 4 FCH 1st 13% pus_org- ng             
2495 1 1/2 FCH 1st 9% pus_org- ng             
2496 33 M 1&2nd⁰ 22% pu+,GNB+ kp/ps S S R R S S R R S R S RECOVERED 
2497 22 F 1&2nd⁰ 17% pus_org- ng             
2504 7 MCH 1st 9% pus_org- ng             
2506 17 M 1&2nd⁰ 43% pu+,GNB+ pm/ec             
2507 18 F 1&2nd⁰ 15% pus_org- ng             
2508 45 M 1&2nd⁰ 22% PUS-ORG- NG             
2509 62 F 1st 14% pus_org- ng             
2561 20 F 1&2nd⁰ 11% pus_org- ng             
2527 60 F 1&2nd⁰ 36% pu+,GNB+ ps             
2530 34 F 2nd&3rd 55% pus+ gnb+ kp S S R R S S S S S S S RECOVERED 
3038 2 mch 1st 9% pus_org- ng             
2431 26 F 2nd&3rd 38% pu+,GNB+ kp/ps S R S S S R R S S S S RECOVERED 
2432 4 MCH 1st SCAB pus_org- ng             
2536 65 F 1st 15% pus_org- ng             
2549 26 F 1&2nd⁰ 18% pu+,GNB+ acin             
2550 45 F 1&2nd⁰ 15% pus_org- ng             
2552 68 F 1st 12% pus_org- ng             
2553 2 1/2 MCH 1&2nd⁰ 14% pu+,GNB+ kp/ps S R S S S R R S S S S RECOVERED 
2554 48 F 1st 11% pus_org- ng             
2557 38 M 1st 12% pus_org- ng             
2559 55 F 1st 12% pus_org- ng             
2574 37 M 1st 11% pus_org- ng             
2575 49 M 1&2nd⁰ 17% pu+,GNB+ ps             
2576 48 F 2nd&3rd 67% pus+ gpc+ sa             
2577 36 F 1&2nd⁰ 14% pus_org- ng             
2578 40 F 1st 10% pus_org- ng             
2580 28 F 2nd&3rd 56% pu+,GNB+ kp S S R R S S S S S S S RECOVERED 
2592 19 F 1st 12% pus_org- ng             
2594 29 F 1st 14% pus_org- ng             
2595 58 M 1st 13% pus_org- ng             
2596 26 M 1&2nd⁰ 14% pus_org- ng             
2599 22 M 1&2nd⁰ 18% pus_org- ng             
2611 25 F 1&2nd⁰ 22% pu+,GNB+ ps             
2613 24 F 1&2nd⁰ 12% pus_org- ng             
2643 29 F 1st 12% pus_org- ng             
2644 42 M 2nd&3rd 32% PUS-ORG- NG             
2647 35 M 1st 10% pus_org- ng             
2648 8 1/2 MCH 1st 10% pus_org- ng             
2898 24 F 1&2nd⁰ 23% PUS-ORG- NG             
2902 9 MCH 1&2nd⁰ 11% pus_org- ng             
2903 5 f 1&2nd⁰ 11% pus_org- ng             
2884 21 m 2nd&3rd 11% pu+,GNB+ ps             
2845 39 F 1st 9% pus_org- ng             
2844 3 1/2 f 2nd&3rd 78% pus+gnb&gpc+ sa/ps             
2843 23 f 1&2nd⁰ 22% pus+ gpc+ sa             
S.NO IP/IR No. Age Sex POD  organism AK GEN COT CIP CTX CAZ CTR CX CPM PIPTAZ MRP OUTCOME 
1 14202 57 f 4th pus-org- ng             
2 2212 27 f 5th pus+gpc+ salec             
3 2010 54 m 8th pus+gnb+ ec             
4 2008 26 f 4th pus+gnb+ ec             
5 2238 51 f 6th pus-org- ng             
6 2174 68 f 7th pus-org- ng             
7 2162 63 f 5th pus+budding 
cells+ 
candida             
8 14237 62 m 7th pus-org- ng             
9 4048 44 m 8th  sa             
10 1238 48 m 5th pus-org- ng             
111 1237 27 f 4th pus-org- ng             
12 1196 76 f 5th pus+gnb+ ec             
13 1228 20 f 6th pus-org- ng             
14 4084 44 m 14th pus+gnb+ kp S S R R R R S S S S S RECOVERD 
15 353/18 59 m 5th pus-org- ng             
16 /2266 27 f 6th pus+gnb+ kp/pm S S R R R S R S S S S RECOVERD 
17 /2153 44 f 8th pus+gpc+ cons             
18 /2155 64 m 6th pus-org- ng             
19 /2160   5th pus-org- ng             
20 /2241 28 m 4th pus+gpc+ cons             
21 /2554 66 f 6th pus-org- ng             
22 /2334 60 m 18th pus-org- ng             
23 /1770 53 m 6th pus-org- ng             
24 /2354 66 f 7th pus-org- ng             
25 /2428 47 m 6th pus-org- ng             
26 2429 54 m 5th pus-org- ng             
27 2423 31 f 5th pus+gnb+ ps             
28 2425 37 f 4th pus+gpc+ sa             
29 2417 30 f 5th pus-org- ng             
30 2420 36 m 3rd  ng             
31 2393 44 f 4th pus-org- ng             
32 2395 55 f 5th pus+gnb+ ec             
33 2396 45 f 4th pus+gnb+ ec             
34 2392 60 m 4th pus-org- ng             
35 2375 54 f 5th pus-org- ng             
36 2376 46 f 5th pus+gnb+ ec             
37 2377 50 f 3rd pus+gnb+ pm/ent             
38 2374 68 m 4th pus-org- ng             
39 2354 66 f 6th pus-org- ng             
40 2353 48 m 4th pus-org- ng             
41 2351 67 m 5th pus-org- ng             
42 2347 65 f 4th pus-org- ng             
43 2345 44 m 5th pus+gpc+ sa             
44 2333 60 f 4th pus+gpc+ entero             
45 2332 60 f 4th pus+gpc+ sa             
46 2317 66 m 5th pus-org- ng             
47 2315 50 m 4th pus+gpc+ entero             
48 2274 35 m 4th pus-org- ng             
49 2372 68 m 5th pus+gpc+ sa             
50 1939 53 f 6th pus+gnb+ ec             
51 1940 53 f 8th pus+gnb+ ec             
52 1942 50 f 7th pus+gnb+ kp/ps S R R R R R R S S S R RECOVERD 
53 2008 28 f 4th pus+gnb+ ec/sa             
54 2009 31 m  pus+gpc+ entero             
55 2023 45 m 6th pus+gnb+ kp/ps S R R R S R S S S S S RECOVERD 
56 2024 61 m 4th pus+gpc+ sa             
57 2053 59 m 5th pus+gnb+ ps             
58 2085 24 f 6th pus+gnb+ ec             
59 2090 60 f 5th pus+gnb+ aec/ps             
60 2153 44 f 4th pus+gpc+ cons             
61 2154 65 m 3rd pus+gnb+ kp S S R R S  R R S S S RECOVERD 
62 2238 51 f 6th pus-org- ng             
63 2266 27 f 4th pus+gnb+ kp/ps R R R R R S S S S R S RECOVERD 
64 2267 66 m 5th pus+gpc+ sa/pm             
65 2268 53 f 4th pus+gnb+ ps             
66 2269 46 m 3rd pus+gpc+ entero             
67 2272 68 m 4th pus+gpc+ sa             
68 2292 48 m 5th pus-org- ng             
69 2274 35 m 5th pus-org- ng             
70 2483 60 m 5th pus-org- ng             
71 10277 33 f 9th pus-org- ng             
72 419 46 f 6th pus-org- ng             
73 420 69 m 5th pus+gnb+ ps             
74 460 48 m 7th pus-org- ng             
75 493 23 m 8th pus-org- ng             
76 459 35 m 5th pus-org- ng             
77 489 31 f 5th pus+gpc+ sa/ec             
78 498 45 f 6th pus+gnb+ sa/kp S S R R R S S R R R S SEPSIIS 
79 513 45 m 5th pus-org- ng             
80 544 52 f 9th pus-org- ng             
81 518 23 f 6th pus+gnb+ ec             
82 569 38 m 5th pus-org- ng             
83 568 23 f 7th pus+gnb+ ps             
84 565 30 f 5th pus-org- ng             
85 579 58 m 9th pus+gnb+ kp S S R R S R S S S S S RECOVERD 
86 595 42 f 6th pus+gnb+ ec             
87 2429 54 m 5th pus-org- ng             
88 2428 47 m 4th pus-org- ng             
89 2449 30 f 5th pus+gnb+ ec             
90 2457 34 f ng pus-org- ng             
91 2485 35 m 5th pus+gpc+ entero             
92 2472 50 m 6th pus+gnb+ acin             
93 2455 43 m 6th pus+gnb+ ec             
94 2517 22 f 8th pus-org- ng             
95 2515 18 f 6th pus+gnb+ ec             
96 2548 39 f 6th pus-org- ng             
97 2524 30 m 6th pus+gnb+ ps/kp S R R R R R R S S S R RECOVERD 
98 2534 45 f 6th pus+gpc+ sa             
99 2531 30 f 30/4 pus-org- ng             
100 2638 46 f 9/5 pus-org- ng             
101 19020 60 f 8/5 pus-org- ngg             
102 15/30 45 m 6th pus+gpc+ sa/lec             
103 33 25 f 5th pus+gnb+ kp R S R R S S R S S S S RECOVERD 
104 36 93 m 4th pus+gpc+ sa             
105 128/51 14 f 4th pus+gnb+ ps             
106 88842/53 50 m 6th pus+gnb+ ec             
107 88412/54 60 m 4th pus+gnb+ kp S S R R S R S S S S S RECOVERD 
108 88818/56 52 f 5th pus+gnb+ ec/acin             
109 3254/17 50 m 6th pus+gnb+ ps             
110 77527/60 56 f 5th pus-org- ng             
111 842167/63 88 m 6th pus+gnb+ kp S S S R S S R S R S S RECOVERD 
112 137/93 62 f 4th pus+gnb+ ec             
113 80718/94 53 f 5th pus+gnb+ ps/ec             
114 477/97 67 m 4th pus+gnb+ ec             
115 87202/101 31 f 3rd pus+gnb+ kp S S R R S R S S S S R RECOVERD 
116 77559/129 54 m 6th pus+gnb+ kp/ps S R R S S R S S S S S RECOVERD 
117 77844/132 42 f 4th pus+gnb+ ec             
118 894/135 83 m 5th pus+gnb+ kp S S R R R R R S S S S RECOVERD 
119 692519/139 31 m 5th pus+gpc+ sa             
120 34731/144 32 m 7th pus-org- ng             
121 208/146 47 f 5th pus+gnb+ ps             
122 88718/147 58 f 5th pus-org- ng             
123 629/169 55 f 8th pus+gnb+ ps             
124 79505/175 74 m 5th pus-org- ng             
125 176 15 m 7th pus-org- ng             
126 976/186 22 f 5th pus-org- ng             
127 1043/202 54 f 5th pus-org- ng             
128 88450/203 48 m 5th pus-org- ng             
129 59/204 48 m 5th pus-org- ng             
130 7279/ 50 m 8th pus+gnb+ ec             
131 7281 65 m 5th pus-org- ng             
132 7706 32 f 9th pus-org- ng             
133 7283/ 76 f 7th pus+gnb+ ec             
134 7302 30 f 7th pus-org- ng             
135 7304 45 f 7th pus-org- ng             
136 7316 21 m 6th pus+gnb+ kp S S R R R S S S S S S RECOVERD 
137 7330 43 m 11th pus+gnb+ kp S S R S R S S S S S S RECOVERD 
138 7332 55 f 5th pus+gnb+ kp S S R R R S S S R S S RECOVERD 
139 7343 56 m 5th pus+gpc+ sa             
140 7352 49 m 7th pus-org- ng             
141 7555 59 f 9th pus-org- ng             
142 7366 63 m 8th pus-org- ng             
143 7361 44 m 5th pus-org- ng             
144 7362 80 m 7th pus+gnb+ kp S R R R R S S S S S S RECOVERD 
145 7363 63 m 6th pus+gnb+ ps             
146 7365 54 m 8th pus+gnb+ ps             
147 7380 45 m 7th pus+gnb+ ec             
148 7381 62 m 8th pus+gnb+ ps             
149 7384 62 m 5th pus-org- ng             
150 7387 27 m 7th pus+gpc+ entero             
151 7499 54 m 8th pus+gnb+ ko R R R R R S S S S S R RECOVERD 
152 7454 50 m 7th pus+gnb+ ko R R R R R S S S S S  RECOVERD 
153 7391 58 m 4th pus-org- ng             
154 7398 27 f 4th pus-org- ng             
155 7449 51 m 5th pus-org- ng             
156 7466 22 m 7th pus-org- ng             
157 7444 55 f 8th pus+gnb+ kp S S S R R S S S R S S RECOVERD 
158 7449 51 m 7th pus-org- ng             
159 7476 36 f 11 pus+gnb+ ec/ent             
160 7478 27 m 12t5th pus+gnb+ ec             
161 7486 38 m 7th pus+gnb+ proteus             
162 7489 56 m 4th pus-org- ng             
163 7490 45 m 7th pus-org- ng             
164 7500 63 m 7th pu+sgpc+ sa             
165 7501 74 m 7th pus+gnb+ kp S S R S R R R S S S R SEPSIS 
166 7507 55 f 7th pus+gnb+ kp S S R S R S S R S S R RECOVERD 
167 7510 47 m 7th pus-org- ng             
168 7511 55 f 7th pusgpc+ sa             
169 7516 75 f 7th pus+gnb+ ec/entero            
170 7524 36 m 7th pus-org- ng             
171 7526 21 f 7th pus+gnb+ ps             
172 7535 80 f 7th pus-org- ng             
173 1902 55 m 7th pus-org- ng             
174 88398/50 60 f 7th pusgpc+ sa             
175 7386 32 f 7th pus+gnb+ ec             
176 7446 70 f 7th pu+sgpc+ entero             
177 1905 60 f 7th pus+gnb+ ec             
178 1958 28 f 7th pus+gnb+ ec/sa             
179 2212 27 f 8th pus+gnb+ sa/ec             
180 2266 27 f 7th pus+gnb+ kp/pm R R R R S R S S S S S RECOVERD 
181 34/7 20 f 4th pus-org- ng             
182 445/ 36 f 10th pus+gnb+ ec             
183 2095 80 m 4th pus-org- ng             
184 2348 27 m 4th pus-org- ng             
185 2423 31 f 4th pus-org- ng             
186 2540 43 m 6th pus+gnb+ ec/pm             
187 2858 58 m 5th pus-org- ng             
188 2859 34 f 5th pus-org- ng             
189 2719 28 f 5th pus-org- ng             
190 2701 38 f 4th pus-org- ng             
191 2832 58 f 4th pus-org- ng             
192 2816 46 f 4th pus+gnb+ ec/ps             
193 2674 37 m 4th pus-org- ng             
194 2837 27 f 6th pus-org- ng             
195 2848 70 f 4th pus-org- ng             
196 2859 34 f 5th pus-org- ng             
197 2858 58 m 4th pus-org- ng             
198 2876 58 m 4th pus+gnb+ ps             
199 2890 35 f 4th pus+gnb+ ps             
200 2910 53 f 4th pus-org- ng             
201 2908 32 f 7th pus-org- ng             
202 2917 33 m 5th pus+gnb+ ps/kp R R R R S R R S S S S RECOVERD 
203 2928 54 f 4th pus-org- ng             
204 2933 34 f 5th pus-org- ng             
205 2944 58 m 6th pus+gnb+ kp/ec S R R S R R S R R S S RECOVERD 
206 2943 34 f 6th pus-org- NG             
207 2942 52 m 5th pus+gnb+ ps             
208 2940 48 m 5th pus+gnb+ acin/ps             
209 2952 37 f 6th pus-org- NG             
210 2972 30 m 5th pus-org- ng             
211 2995 11 f 4th pus-org- ng             
212 2994 50 f 4th pus-org- ng             
213 2993 25 f 5th pus-org- ng             
214 2992 23 f 4th pus-org- ng             
215 2998 50 m 4th pus+gnb+ ps/kp R S R R R R S S S S S RECOVERD 
216 3014 35 f 3rd pus-org- ng             
217 3024 35 f 5th pus-org- ng             
218 2425 31 f 6th pus-org- ng             
219 3022 32 f 5th pus-org- ng             
220 3026 58 m 4th pus+gnb+ ps/ec             
221 3044 27 f 4th pus-org- ng             
222 3041 22 f 5th pus+gnb+ sa/kp S S R R R S S S R S S RECOVERD 
223 3063 30 f 4th pus-org- ng             
224 323 46 f 5th pus-org- ng             
225 188 55 f 8th pus+gnb+ ec/kp S S R S S R S R R S S RECOVERD 
226 187 28 m 6th pus-org- ng             
227 208 68 m 7th pus+gnb+ pm/ent             
228 204 48 m 4th pus-org- ng             
229 202 54 f 7th pus+gnb+ ps/sa             
230 247 40 f 8th pus+gnb+ ko R R R R R R R S S S S RECOVERD 
231 254 58 f 5th pus-org- ng             
232 267 26 f 7th pus-org- ng             
233 292 48 f 6th pus-org- ng             
234 322 67 m 5th pus-org- ng             
235 369 44 f 5th pus-org- ng             
236 364 15 f 6th pus-org- ng             
237 204/59 48 m 13th pus+gnb+ acin             
238 459/77198 35 m 7th pus-org- ng             
239 LRN0 AGE SEX POD gm stain org AK GEN COT CIP CTX CAZ CTR CX CPM PIPTAZ MRP OUTCOME 
240 9149 59 m 10 pus-ogr_ ng             
241 9354 18 m 20 pus-ogr_ ng             
242 13623 47 m 6 pus-ogr_ ng             
243 3352 35 m 5 pus-ogr_ ng             
244 9963 38 m 10 pus+org- ng             
245 9489 60 f 5 pus+org- ng             
246 2236 66 m 15 pus+org- ng             
247 97159 67 M 1month pus+org- sa             
248 2234 14 mch 4 pus+org- ng             
249 14830 54 m 8 pus+gpc+ sa             
250 13623 47 m 6 pus-ogr_ ng             
251 2088 28 m 20 pus-ogr_ ng             
252 13848 18 m 5 pus_gnb+ ec             
253 2158 39 m 2months pus-ogr_ ng             
254 2125 14 mch 8 pus-ogr_ ng             
255 2576 57 m 11 pus-ogr_ ng             
256 2478 60 f 9 pus_gnb+ kp/pm S S R S R R S R S S S RECOVERE 
257 2479 67 m 25 pus-org+ acin             
258 2488 52 m 14 pus-ogr_ ng             
259 2523 48 m 6 pus-ogr_ ng             
260 2570 57 m 7 pus-ogr_ ng             
261 2609 14 mch 5 pus-ogr_ ng             
262 2586 28 m 11 pus-ogr_ ng             
263 2641 65 f 9 pus+gpc+ cons             
264 2664 60 f 5 pus-ogr_ ng             
265 17738 51 f 4 pus-ogr_ ng             
267 19387 35 m 7 pus-ogr_ ng             
268 2689 15 mch 5 pus_gpc+ sa             
269 2684 72 m 17 pus-ogr_ acin             
270 2430 40 m 4 pus-ogr_ ng             
271 2070 38 m 6 pus-ogr_ ng             
272 2071 60 m 7 pus_gpc+ ec/sa             
273 24214 40 m 6 pus-ogr_ ng             
274 920 50 m 5 pus-ogr_ ng             
275 78989 36 f 5 pus-ogr_ ng             
276 75408 60 m 8 pus-ogr_ ng             
277 7291 32 m 6 pus_gpc+ sa             
278 7292 26 m 4 pus-ogr_ ng             
279 7306 12 fch 6 pus-ogr_ ec             
280 7309 32 m 7 pus-ogr_ ng             
281 7310 63 m 10 pus+gpc+ sa             
282 7322 83 m 8 pus-ogr_ sa             
283 7326 75 m 5 pus-ogr_ cons             
284 2236 66 m 13 PUS+GNB+ kp S S R R R S S S R S S RECOVERE 
285 7329 25 m 6 pus-ogr_ ng             
286 7353 35 m 5 pus-ogr_ ng             
287 7367 54 m 7 pus-ogr_ ng             
288 7388 28 m 18 pus-ogr_ ng             
289 7394 32 m 7 pus-ogr_ ng             
290 7995 60 m 6 pus-ogr_ ps             
291 7448 55 m 8 pus_gpc+ sa             
292 7443 59 m 5 pus-ogr_ ng             
293 7447 45 m 6 PUS+GNB+ kp S S R R R S S S R S S RECOVERE 
294 7448 55 m 6 pus-ogr_ ng             
295 7463 16 m 7 pus+gpc+ sa             
296 7473 13 fch 2months pus-ogr_ ng             
297 7515 75 m 5 pus-ogr_ ng             
298 3820 20 m 7 PUS+GNB+ kp S S R R R S S  S S S RECOVERE 
299 4554 60 f 6 pus-ogr_ ng             
300 4547 41 m 4 pus+gpc+ sa             
Column12 Column2 Column3 Column4 Column5 Column6 Column8 AK GEN COT CIP CTX CAZ CTR CX CPM PIPTAZ MRP OUTCOME 
 Sex AGE Duration Glucose Level gmstain Organism             
1 m 46 30days 121 pus+gpc+ sa             
2 m 66 60days 115 pus+gnb+ ps             
3 m 54 30days 180 pus-org- ng             
4 m 59 30days 200 pus-org- ng             
5 m 46 12 days 150 pus-org- ng             
6 m 88 30days  pus+gnb+ kp S S R R R S  S S S S amputated 
7 m 78 30days 132 pus+gnb+ pm/ec             
8 m 42 18days 258 pus+gnb+ kp S S R R R S  S S S S HEALED 
9 m 68 90days 254 pus+gpc+ sa             
10 m 65 20days 176 pus-org- ng             
11 m 50 90days 233 pus+gnb+ ec/entero             
12 m 53 30days 323 pus+gnb+ kp/ps S S R R R S  S S S S NO FOLLOWUP 
13 m 55 60 days 213 pus-org- ng             
14 m 58 90days 225 pus+gnb+ ps             
15 m 78 10 days  pus-org- ng             
16 m 74 150days 200 pus+gpc+ sa             
17 m 43 150days 117 pus+gnb+ sa/ps             
18 m 65 6 yrs 300 pus-org- ng             
19 m 69 5months 433 pus+gnb+ kp S S R R R S  S S S S amputated 
20 f 76 20days 150 pus+gnb+ ec             
21 m 55 2months 143 pus+gnb+ ec             
22 f 52 1month 123 pus+gpc+ sa             
23 m 74 4month 245 pus+gpc+ ps/sa             
24 m 59 1month 109 pus+gpc+ ng             
25 m 66 15 days 194 pus-org- ng             
26 f 58 4 weeks 200 pus-org- ng             
27 m 73 3weeks 178 pus+gnb+ pm             
28 m 65 25days 189 pus_org_ ng             
29 m 62 4month 233 pus_org_ ng             
30 f 54 20 days 145 pus+gnb+ pm             
31 m 55 2months 211 pus-org- ng             
32 f 60 15days  pus-org- ng             
33 M 66 2months 178 pus-org- ng             
34 m 73 3months 132 pus+gnb+ ps/kp S S R R R S  S S S S NO FOLLOWUP 
35 m 57 1 month 152  ng             
36 m 56 6month 233 pus+gnb+ sa/kp S S R R R S  S S S S amputated 
37 m 55 1 week 146  ng             
38 f 49 1 month 150 pus+gnb+ ps/kp S S R R R S  S S S S HEALED 
39 m 59 20 days 176 pus+gpc+ ps             
40 m 73 1month 152 pus-org- ng             
41 m 70 1month 187 pus-org- ng             
42 m 63 34days 132 pusgnb+ kp/sa S S R R R S  S S S S HEALED 
43 m 61 30days 344  kp S S R R R S  S S S S HEALED 
44 f 57 5months 213 pus-org- ng             
45 m 52 23days 123 pus-org- ng             
46 f 57 1month 156  ec             
47 m 85 30days 204 pus-org- ng             
48 f 79 18 days  pus-org- ng             
49 m 49 1month 200  ng             
50 m 57 2months 204 pus-org- ng             
51 m 46 15days 176 pus-org- ng             
52 m 66 10days 189 pus-org- ng             
53 f 54 4month 254  ps             
54 m 59 1month 165 pus-org- ng             
55 f 46 20days 233 pus-org- ng             
56 m 88 45days 200 pus-org- ng             
57 m 78 1month 199 pus+gnb+ acin             
58 m 42 3months 233 pus_org_ ps             
59 m 68 23days 213 pus-org- ng             
60 m 65 2months 234 pus+gnb+ kp/ps S S R R R S  S S S S NO FOLLOWUP 
61 m 50 26days 213 pus+gnb+ ng             
62 m 53 32days 165 pus+gnb+ ec             
63 m 55 45days 345 pus+gnb+ ec             
64 f 58 2months 342 pus+gnb+ ng             
65 f 78 10days 211 pus+gnb+ ng             
66 m 74 4month 134 pus+gnb+ ps             
67 m 43 23days 237 pus-org- NG             
68 m 65 6month 187 pus+gpc+ sa             
69 m 69 2months 145 pus+gnb+ ps             
70 m 76 33days 176 pus+gnb+ ps             
71 m 55 1month 256 pus+gnb+ ps             
72 m 52 25days 233  pm             
73 m 74 1month 256 pus+gnb+ kp S S R R R S  S S S S NO FOLLOWUP 
74 m 59 14days 254 pus+gpc+ sa             
75 m 66 2months 243 pus+gpc+ sa             
76 m 58 2months 156 pus+gnb+ ps             
77 f 73 15days 344  ng             
78 f 65 3months 200 pus+gnb+ Ps/sa             
79 m 62 2months 187 pus-org- ng             
80 m 54 2months 144 pus+gpc+ ps/cons             
81 m 55 17days 231 pus+gpc+ sa             
82 f 60 5months 234 pus+gpc+ sa/pm             
83 m 66 15days 111 pus+gpc+ sa             
84 m 73 1month 213 pus+gnb+ acin             
85 m 57 4month 234 pus-org- ng             
86 m 56 2months 267 pus-org- ng             
87 m 55 3months 198 pus+gnb+ ps             
88 m 49 5months 233 pus+gnb+ kp S S R R R S  S S S S HEALED 
89 f 59 45days 248 pus+gpc+ sa             
90 m 73 21/2months 156 pus+gnb+ ng             
91 m 70 3months 186 pus-org- ng             
92 m 63 34days 256 pus-org- ng             
93 f 61 2months 189 pus-org- ng             
94 m 57 18days 245 pus+gnb+ kp S S R R R S  S S S S HEALED 
95 f 52 6month 243 pus+gnb+ kp S S R R R S  S S S S HEALED 
96 f 57 1month 321 pus+gnb+ acin             
97 m 85 10days 189 pus-org- ng             
98 m 79 1month 123 pus+gnb+ Ps/acin             
99 m 49 2months 234 pus+gpc+ sa             
100 f 57 1month 176 pus-org- NG             
                   905364 16 f breastabscess pus-org- ng             
14425 8 fch abscessin kneejoint pus-org- ng             
2254 62 m bedsores  pus-org- ng             
15232 53 m bedsores  pus+gnb+ ec             
14670 27 f breastabscess pus+gpc+ sa             
2005 65 m abscess in R.shoulder pus+gnb sa/kp S S R R R R S S S S S RECOVERD 
2086 50 f bed sores pus-org- ng             
2118 28 m abscessin R.arm pus+gnb NG             
2226 35 f pressureulcer pus+gnb kp S R R S R S S S S S S RECOVERD 
2227 45 f bedsores  pus-org- ng             
2228 20 f breastabscess pus+gpc+ sa             
2289 35 m abcess in anteriorabdominal pus-org- ng             
2290 18 m pondst infectious wou pus-org- ng             
2295 45 f chronic aenous ulcer pus-org- ng             
2311 60 f beored sores pus+gpc+ ent             
2421 22 f abscess in L.leg pus-org- ng             
2424 21 f abscess in chin pus+gpc+ sa             
88153 10 mch postinfectious wound pus-org- ng             
109 40 f glutealabscess pus-org- ng             
2061 47 m pressureulcer pus-org- ng             
2637 32 f abscessin 4th finger pus+gpc+ sa             
2475 45 m bedsores  pus+gpc+ sa             
2480 30 m postinfectious wound pus+gnb ec             
2607 43 m abscessingreat toe pus+gpc+ sa             
2621 33 f breastabscess pus-org- ng             
2632 50 m pressureulcer pus-org- ng             
2649 71 f bedsores  pus+gnb ec             
2658 40 m abcess in anteriorabdominal pus+gnb NG             
2057 22 m abscessin littlefinger pus+gpc+ sa             
2483 26 m glutealabscess pus-org- ng             
2826 60 m trophiculcer pus-org- ng             
1363 55 m bedsores  pus+gnb NG S            
849525 59 m abcsessinleg pus-org- ng             
84925 35 m abscessin r.4th finger pus+gnb pm/ps             
22767 50 m postinfectious wound pus+gpc+ sa             
8522430 45 m bedsores  pus+gnb ec             
1883 60 m pressureulcer pus-org- ng             
1931 24 m abscess in great toe pus-org- ec             
1956 23 m abcessin theR.CERVICAL pus+gnb kp/pm S S R R R S S S R S S RECOVERD 
1963 64 m bedsores  pus-org- ng             
1978 63 m pressureulcer pus-org- ng             
1983 63 m abscess in great toe pus+gnb ec             
2001 25 m AbscessinL.hand pus-org- ng             
2057 22 m Ascessin L.ankle pus+gpc+ sa             
2105 65 m bedsores  pus+gpc+ sa             
2106 45 m postinfectious wound pus-org- ng             
2115 30 m abcessinR.THIH pus+gpc+ sa             
2281 20 m abscessinLmiddlefinger pus+gpc+ sa             
2287 35 f breastabscess pus-org- ng             
17939 52 m pressureulcer pus-org- ng             
3064 36 m abscessin rleg pus-org- ng             
3041 22 f breastabscess pus+gnb sa/kp S S R R S R S S S S S RECOVERD 
3045 18 m abscessin rleg pus-org- ng             
3028 85 f bedsores  pus-org- ng             
3021 18 m glutealabscess pus-org- ng             
3024 18 m abscessin greattoe pus+gnb ps/ec             
3014 3 mch glutealabscess pus-org- ng             
2954 16 m asbscessin leg pus+gnb ps/ec             
2894 23 f breastabscess pus-org- ng             
2834 58 m bedsores  pus-org- ng             
1838 54 m abcessin l.hand pus-org- ng             
2808 43 m submandibularabscess pus-org- ng             
2826 60 m trophiculcer pus-org- ng             
2854 45 f cervical ln abscess pus-org- ng             
2445 43 m abscess in anterior abdominalwall pus+gnb+ ec             
2475 45 m abscessl.leg pus+gpc+ sa             
2480 30 m glutealabscess pus+gnb+ ec             
2486 55 f bedsores  pus_budding cells candidasps            
2541 26 f abscessin shoulder pus-org- ng             
2567 29 m abscessin cheek pus-org- ng             
2607 43 m AbscessL.hand pus-org- sa             
2620 65 m bedsores  pus-org- ng             
2621 23 f breastabscess pus-org- ng             
2631 58 f pressureulcer pus+gnb+ ps/ec             
2632 50 m abscessin kneejoint pus-org- ng             
2649 71 m bedsores  pus+gnb+ ec             
2658 40 m abscessinn leg pus+gnb+ NG             
2522 60 f glutealabscess pus-org- ng             
2448 35 m bedsores  pus+gnb+ ps/ec             
2433 26 m glutealabscess pus-org- ng             
575 65 f pressureulcer pus+gnb+ kp S S R S R S S S R S S RECOVERD 
444 42 f abscessinshoulder pus-org- ng             
469 38 f abscessin ant abdominalwall pus-org- ng             
2446 38 m pressureulcer pus+gpc+ ent             
426 23 f abscessin L.hand pus+gpc+ sa             
418 42 m pressureulcer pus-org- ng             
421 45 m abscessin kneejoint pus+gnb+ ec             
393 50 m abscessingreat toe pus-org- ng             
317 59 m abscessin r.hand pus+gnb+ kp S S R R R S S S S S S RECOVERD 
321 35 m abscessin leg pus+gnb+ proteus             
211 19 m abscessin shoulder pus-org- ng             
551 70 m bedsores  pus-org- ng             
1928 43 m bedsores  pus-org- ng             
2444 50 m pressureulcer pus-org- ng             
1678 28 f abscess  pus+gpc+ sa             
543 23 m abscess  pus_+gnb+ ec             
243 56 f pressureulcer pus-org- ng             
1094 65 m bedsores  pus-org- ng             
2367 45 m abcess  pus-org- ng             
2000 38 m abcess  pus+gnb+ ec             
 
